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Prostate cancer is currently the third commonest malignancy among Singaporean men. 
The increase can be attributed to an aging population, serum PSA screening and the 
application of transrectal ultrasound needle biopsy, which is the current gold standard for 
diagnosis of prostate cancer. 
 
Radical prostatectomy is currently the treatment given to male patients with localized 
prostate cancer, and who are likely to benefit from the procedure. While serum PSA is 
used to monitor the risk of biochemical recurrence after radical prostatectomy, 
controversies surrounding the usefulness of serum PSA has led to a need for biomarkers 
which can prognosticate disease aggressiveness and predict treatment outcome, and also, 
better understanding of the pathogenesis. 
 
For this project, 170 cases of prostatic acinar adenocarcinoma of male patients who 
underwent radical prostatectomy at Singapore General Hospital from 2002 to 2005 were 
being studied. Tissue microarrays (TMA) were constructed from whole mount 
preparations of these radical prostatectomy specimens. Clinical details such as age, 
ethnicity, pre- and post-operative serum PSA, histopathological parameters such as 
histological types, Gleason score, size of tumour, location of tumour, extent of tumour, 
presence or absence of perineural invasion, vascular/ lymphatic invasion, associated high 
grade prostatic intraepithelial neoplasia as well as involvement of surgical margins were 








Immunohistochemical staining was performed on TMA sections using androgen receptor 
(AR), p53, Ki-67 Her-2/neu and neuroendocrine markers – synaptophysin (Syn), 
chromogranin A (Chr A) and CD56 antibodies. These sections were then scored and 
statistical analysis was performed using SPSS, student t test and Chi Square Test. 
 
This study found Ki-67 and p53 to be associated with adverse pathological variables – 
Ki-67 was positively correlated to PSA level as indicated by a p value of 0.041 while p53 
intensity was positively correlated to Gleason score as indicated by p value of 0.018. Ki-
67 and p53 were also observed to be positively correlated with AR. Ki-67 
immunoreactive score (IRS) was positively correlated to AR IRS as indicated by p value 
of 0.055; p53 intensity-percentage score (IPS), p53 IRS were positively correlated to AR 
IPS and AR IRS as indicated by p value of 0.041 and 0.015 respectively. 
 
Correlations between Her-2/neu, neuroendocrine markers and clinicopathological 
parameters did not yield any significant statistical p values. This could be due to the 
relatively small case numbers that were positive for the various markers. 
 
Further studies may include enlarging the patient cohort and widening the panels of 
antibodies to be evaluated, in order to glean knowledge on the role of biological markers 
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According to the “Trends in Cancer Incidence in Singapore 1968-2007”, Singapore 
Cancer Registry Report Number 7,  published by the Singapore Cancer Registry, prostate 
cancer is currently the third most common cancer among Singaporean males, accounting 
for 9.8% of all cancers in local men (Lee et al, 2008).  Prostate cancer is also the third 
most prevalent cancer among Chinese, Malay and Indian males in Singapore. The 
increase in incidence can be attributed to an aging population, the advent of serum 
prostate specific antigen (PSA) screening and the ready availability of transrectal 
ultrasound guided prostatic core biopsies. 
 
Serum PSA is currently the screening modality for early detection of prostate cancer. The 
absolute serum level of PSA can also predict potential aggressiveness of a prostate cancer. 
In Singapore, a PSA value more than 4ng/ml will generally indicate the possibility of 
prostate cancer in an adult man, for which a subsequent transrectal ultrasound guided 
prostate needle biopsy, which is the gold standard for confirmation of prostate cancer, 
may be conducted. Radical prostatectomy and/or radiation therapy may be the treatment 
modalities depending on Gleason scores and quantum of the cancer discovered on the 








Table 1. Ten Commonest Cancers Diagnosed in Singaporean Males from 2003 – 
2007 
 
Rank Site      Number of Males       Percentage 
       Diagnosed              (%)  
1          Colo-rectum                                 3902                                     18.4 
2          Lung                                             3828                                     17.6 
3          Prostate                                        2169                                       9.8 
4          Liver                                             1700                                       7.9 
5          Stomach                                        1375                                       6.6 
6          Lymphoid Neoplasm                    1309                                       5.8 
7          Nasopharynx                                 1198                                       5.5 
8          Skin, including melanoma              973                                        4.3 
9          Bladder                                            675                                         2.9 
10        Kidney and other urinary               620                                        2.7   
 
Adapted from Trends in Cancer Incidence in Singapore 1968-2007, Singapore Cancer Registry Report No. 
7, Singapore Cancer Registry, Page 31, 33 
 
1.2 Anatomy of Prostate 
The prostate gland, about the size of the walnut, weighs about 20gm upon maturity (Lee 
et al, 1994). The gland is found low in the pelvis minor, surrounds the bladder neck 
(Young and Heath, 2002) and the first part of the urethra, and is posterior to the 
symphysis pubis. The gland lies ventral to the ampulla of the rectum, where the posterior 
portion of the prostate can be easily palpated (Lee et al, 1994). 
 
The prostate is made up of branched tubulo-acinar glands and fibromuscular tissues, 
enclosed in a fascial sheath (Lee et al, 1994). A partial capsule encloses the posterior and 
lateral aspects of the prostate while the anterior and apical surfaces are bounded by the 
anterior fibromuscular stroma. (Young and Heath, 2002). The anterior fibromuscular 





the anterior part of the prostate and merges with the sphincter at the bladder neck 
(Kissane, 1997). 
 
The prostate consists of 4 zones, namely the transition zone, central zone, peripheral zone 
and the anterior fibro-muscular stroma. The transition zone, which surrounds the 
proximal prostatic urethra, consists of about 5% of the gland and is found at the junction 
of the proximal and distal segments of the urethra. The transition zone is important in that 
it can undergo hyperplasia, resulting in the formation of nodules known as benign 
prostatic hyperplasia which may lead to clinical symptoms of prostatism such as urinary 
frequency, hesitancy and dribbling.   
 
The central zone, making up 20% of the glandular tissue, surrounds the ejaculatory ducts, 
extending out from the verumontanum in a wedge-shaped fashion. The largest zone, 
which is the peripheral zone, completes the remaining 70% of the prostate, and is also 





                                                    
Figure 1 Functional zones of prostate gland. 




Three basic cell types, namely the secretory, basal and neuroendocrine can be found in 
the prostate glands. The secretory cells, forming a continuous layer facing the glandular 
lumen, extend throughout the ducts and acini. Secretory cells may produce substances 
such as lactoferrin and neutral mucin. These cells also contain low-molecular weight 
cytokeratins and receptors for androgen, estrogen, progesterone and lectin. More notably, 
secretory cells are important in that they produce and store PSA and an isoenzyme of 
prostatic acid phosphatase (PAP) (Kissane, 1997). 
 
Basal cells, forming a discontinuous layer at the antiluminal surface of the prostatic 
epithelium, are more commonly seen in the peripheral rather than in the central glands. 
These cells do not secrete any substances, although they are immunoreactive to many 
high-molecular cytokeratins – the presence of basal cells can be demonstrated by 





their identification precludes prostate cancer, since basal cells are absent in prostate 
adenocarcinoma.  Basal cells are insufficiently differentiated to be considered 
myoepithelium. 
 
Neuroendocrine cells are often demonstrated by argentaffin-argyophil histochemical 
stains. With advances in immunohistochemistry, neuroendocrine expression can now be 
detected by various neuroendocrine markers, notably chromogranin A and synaptophysin.  
 
Collagen, smooth muscle fibers, elastic fibres, lymphatic and blood vessels, nerves, 
scattered foci of lymphocytes, make up the prostatic stroma. Fibroblasts and collagen 
fibers occur in parallel arrangement; the discovery of nerve fibers circumferentially 
surrounded by acini is a feature of prostatic carcinoma (Kissane, 1997, Epstein and 
Murphy, 1997). 
 
Prostate development arises from the urogenital sinus and is dependent on androgen and 
5-α dihydrotestosterone (5α-DHT) which is a metabolite of fetal testosterone. It has also 
been suggested that primitive prostatic mesenchyme is the target tissue for 5-α 
dihydrotestosterone and not the epithelium lining the urogenital sinus (Kissane, 1997, 
Epstein and Murphy, 1997).  
 
5α-DHT is the most potent natural male hormone as well as natural ligand for androgen 
with a Kd = 10-11M (Penning et al, 2008, Penning et al, 2007, Bauman et al, 2006). 5α-





functions of the human prostate (Bauman et al, 2006, Rizner et al, 2003, Davies and 
Eaton, 1991). 5α-DHT is formed when testosterone from Leydig cells of the testis is 
reduced by the action of 5α-reductase type 2 in the prostate  (Penning et al, 2008, 
Penning et al, 2007, Bauman et al, 2006, Rizner et al, 2003). Regulation of 5α-DHT is 
regulated by 3α/3β-hydroxysteroid dehydrogenase (3α-HSD) (Penning et al, 2008, Rizner 
et al, 2003). 
 
Overproduction of 5α-DHT can lead to either benign prostatic hyperplasia (BPH) or 
prostate cancer (Rizner et al, 2003).  Excess 5α-DHT production may be caused by 
elevated 5α-DHT synthesis as a result of increased expression of 5α-reductase type 2 or 
increased expression of the oxidative 3α-HSD isoforms which convert 3α-diol to 5α-DHT 
or decreased inactivation of 5α-DHT due to the downregulation of 3-ketosteroid 
reductase (Rizner et al, 2003).  
 
1.3 Risk Factors 
The risk factors which may contribute to the development of prostate cancer remain 
relatively unknown although several efforts have been made to study whether age, 
familial inheritance, racial groups, diet and even exposure to certain chemicals as a result 
of occupational hazards, play a role in the development of prostate cancer. In addition, 
there are a number of studies reporting on ethnicity as a risk factor, with black men 
reportedly at highest risk (Boyle and Severi, 2003, Hoffman, 2006, Pomerantz et al, 2007, 





It is difficult to study the risk factors associated with prostate cancer, be it case-control 
studies or prospective cohort studies, as reported by Boyle and Severi (Boyle and Severi, 
2003) and Wolk (Wolk, 2005). Boyle and Severi also suggested that the obstacles faced 
when designing studies to evaluate various risk factors associated with prostate cancer 
were probably due to paucity of information relating to disease specificity, the 
heterogeneous nature of phenotypes and genotypes of prostate cancer, which make 
pathogenesis challenging to elucidate (Boyle and Severi, 2003). 
 
Neverthless, Boyle and Severi and Wolk, had reported age being an established risk 
factor associated with prostate cancer. This could be due to the fact that prostate cancer is 
not frequent before the age of 50. In fact, Obek et al even suggested that age could be an 
independent parameter in administration of treatment due to its direct impact on mortality 
(Obek et al, 1999).  However, Obek et al also reported that the studies available were not 
conclusive enough to determine age as a prognostic factor for biochemical recurrence 
after radical prostatectomy (Obek et al, 1999). 
 
Family history and genetics as risk factors for prostate cancer had been well studied 
(Boyle and Severi, 2003, Lichtenstein et al, 2000, Wolk, 2005). Boyle and Severi 
reported that prostate cancer presented familial aggregation, which was similar to breast 
and colon cancers. Linkage analyses, polymorphism studies were carried out to better 
understand the relationship of gene mutation and risk of prostate cancer (Boyle and 






Hormones and growth factors were also being suggested to be risk factors associated with 
prostate cancer (Boyle and Severi, 2003). The normal prostate epithelium growth and 
maintenance were regulated by the androgen and vitamin D pathways – androgen 
stimulates prostate cell proliferation while vitamin D inhibits proliferation, hence, it was 
believed that high levels of vitamin D was therefore associated with lower risk of prostate 
cancer (Boyle and Severi, 2003). 
 
Besides genetic factors, growth factors and hormones reported to be risk factors 
associated with prostate cancer, environmental factors such as diet, lifestyle, and type of 
occupation, were also being studied to evaluate the association between these factors and 
risk of prostate cancer. 
 
Boyle, Severi, Chan and Wolk, (Boyle and Severi, 2003, Chan et al, 1998, Liang and 
Liao, 1992, Wolk, 2005) reportedly found a positive association between prostate cancer 
and consumption of meat and dairy products. Boyle, Severi and Wolk suggested that 
when meat was cooked at high temperatures, such as grilling, carcinogenic substances 
such as heterocyclic amines and polycyclic aromatic hydrocarbons, were produced. Wolk 
also reported that consumption of dairy products was associated with increasing risk of 
prostate cancer, yet the mechanisms involved in prostate cancer tumorigenesis were not 
well studied. Kolonel (Kolonel, 2001) also reported inconsistent findings of association 






Previous studies also reported a weak association between body mass index (BMI) and 
risk of prostate cancer (Lund Nielsen et al, 2000, Severson et al, 1998 ).  
 
Types of occupation were also thought to be risk factors associated with prostate cancer, 
but there was also a lack of significant findings to support a specific relationship (Boyle 
and Severi, 2003, Lee et al, 1994). 
 
While these risk factors might not be direct risk factors associated with prostate cancer, 
the observations associated with these factors could be useful as measures to be 
considered when managing prostate cancer in male patients. 
 
 1.4 Radical Prostatectomy 
Radical prostatectomy is the treatment for localized prostate cancer and is performed 
when there is a high likelihood of cure, reportedly with 10- and 15- year disease-free 
survival rates (Lee et al, 1994). Radical perineal prostatectomy was introduced in 1904 
by Hugh Hampton Young who suggested this method will allow better understanding of 
the disease (Von Eschenbach, 1981). By 1979, radical anatomic prostatectomy which was 
developed by Walsh and Partin was easier to perform, with less blood loss and fewer side 
effects (Walsh and Partin, 1994). Walsh then introduced radical nerve-sparing 
prostatectomy in 1982 (Walsh and Partin, 1994). By 1981, Von Eschenbach (Von 
Eschenbach, 1981) reported that the retropubic radical prostatectomy was preferred by 
many surgeons instead of the perineal approach as it allowed access to and surgical 





Radical prostatectomy involves complete removal of the prostate, seminal vesicles and 
adjacent tissues. Margins such as apex and base were also removed for histological 
investigation (Srigley, 2006). Pelvic lymph nodes were also occasionally sampled. After 
the procedure, the radical prostatectomy specimen is fixed in 10% buffered formalin 
overnight prior to assessment by pathologist. 
 
Pathologic evaluation of the radical prostatectomy specimen will give an insight on the 
prognosis, which will aid in further management of the patient. Gleason score, tumour 
size (in terms of volume), pathological stage, location and multifocality of tumour, 
lymphovascular and perineural invasion can be determined on the radical prostatectomy 
specimen.  
 
One of the main disadvantages of radical prostatectomy is that it is a major operation and 
could result in damage to structures around the prostate gland (Brawley et al, 2007). 
However, with advances made to the procedure including laparoscopic and robotic 
approaches, operative risks including postoperative morbidities such as urinary 
incontinence and impotence are remarkably reduced. 
 
1.5 Management of Prostate Cancer 
Patients with localized prostate cancer are usually offered radical prostatectomy. There 
are, of course, patients with localized prostate cancer who are also treated by 





co-morbidities. However, the true benefit of this treatment has been reported to be 
difficult to evaluate (Lee et al, 1994, Moul, 2006). 
 
Androgen ablation is another form of therapy for prostate cancer patients. As androgen 
receptors are found to be involved with prostate cancer progression, it is thought that 
administering antiandrogens to patients, especially those with metastatic disease, will be 
beneficial. Flutamide, bicalutamide, nilutamide, are some antiandrogens approved by 
Food and Drug Administration (FDA) for use on humans. Bicalutamide has been 
extensively studied and has been found to improve the quality of life, and probably 
survival. Flutamide, however, is reportedly not as promising as bicalutamide due to 
inconclusive findings (Moul, 2006). 
 
5-alpha-reductase inhibitor – finasteride, is administered at 10mg daily to patients who 
have PSA-only recurrence after radical prostatectomy However, this approach was not 
reported to be accompanied by a drop in serum PSA level, which is often an indication 
that the cancer has been controlled (Moul, 2006). 
 
Combination therapy has been reported to have a better outcome than monotherapy in 
high grade prostate cancer. However, longer follow-up periods are required to better 
understand the benefits of combination therapy. Also, administering bicalutamide with 5-







1.6 Gleason Grading System 
The Gleason grading system used for prostate cancer was developed in 1966 by Donald 
F.Gleason, whereby the cancer was graded based on the morphology of the tumour. 
Gleason score is reported as a sum of the primary (most predominant as determined by 
area of involvement) and second most predominant patterns (Patel et al, 2007, Srigley, 
2006). There are 5 grades assigned to each primary and secondary pattern. Each grade 
describes a glandular pattern, with grade 1 being the best differentiated and grade 5 
representing the worst or least differentiated pattern (Srigley, 2006, Epstein and Murphy, 
1997).   The Gleason sum or score is calculated by adding the most predominant or 
primary cancer pattern to the secondary or second most predominant pattern. The primary 
and secondary grades of the most predominant and the second most predominant patterns 
are then summed up to give a final Gleason score. At times, when the tertiary pattern is 
also significant, especially in radical prostatectomy specimens, the tertiary Gleason grade 
will be reported but not included in the final Gleason score. 
 
Gleason scores range from 2 to 10, with the 5-8 range being the most common. Srigley 
(Srigley, 2006) reported that low Gleason grade tumours were usually located in the 
transition zone of the prostate gland, and higher Gleason scores, for instance 7, were 
often found in the peripheral zone and associated with worse prognosis. Gleason scores 
are determined in all radical prostatectomy specimens, as the score also aids in predicting 






Gleason grade 1 tumours consist of circumscribed nodules of uniform, single glands 
which are closely packed. The glands in Gleason grades 1 and 2 are also larger than those 
of higher Gleason grades. Gleason grade 1 and 2 patterns are associated with cells with 
abundant and pale cytoplasm (Brawley et al, 2007). 
 
Gleason grade 2 tumours are rather well circumscribed but tend to infiltrate beyond the 
lobular margins into the nearby non-neoplastic gland. The glands are loosely arranged 
and less uniform that those in grade 1.  
 
Gleason grade 3 tumours infiltrate within non-neoplastic prostatic lobules. The sizes and 
shapes of the glands are more variable. The glands can be large and cribriform, and are 
considered Gleason grade 3 as long as the glands are not coalescent and still maintain 
their rounded contours. 
 
Gleason grade 4 glands, on the other hand, are coalescent and fused, with some abortive 
glandular profiles. Cribriform patterns can be seen but the contours are now irregular and 
the glandular outlines larger. These cells may have pale to clear cytoplasm. 
 
Gleason grade 5 glands are made up of sheets, cords, single cells or solid nests. The 
glands have sparse or no lumina. Comedonecrosis is also seen in Gleason grade 5 






The critical importance of pathologic assessment of prostate cancer to therapy and 
prognostication calls for reproducibility, consistency and consensus on Gleason grading. 
With PSA screening becoming more common and use of multiple needle biopsies to 
detect prostate cancer, immunohistochemistry as an adjunct to prostate cancer diagnosis 
has become more frequently used.  Variants of prostate carcinoma that have implications 
for treatment and prognosis need to be accurately identified and communicated to the 
managing clinicians. 
 
1.7 Prostate Specific Antigen (PSA) Screening and Pitfalls 
For many years now, serum PSA has been the method of choice for screening as well as 
detecting biochemical recurrence post-treatment of prostate cancer. And it has also been 
widely accepted that a serum PSA level of more than 4ng/ml is usually indicative of 
probable prostate cancer (Shariat et al, 2007).While serum PSA still retains an important 
role in the prognostication of prostate cancer, there are additional markers that are 
currently being investigated to assess the aggressiveness of the cancer.  
 
PSA is a single chain, serine protease glycoprotein, with a molecular weight of 34,000 
daltons and is produced  by the epithelial cells of the prostate gland, even when the gland 
is hyperplastic or cancerous. Its level is one million fold higher in prostatic fluid than in 
serum. PSA functions in liquefying the seminal coagulum, and is contained within the 
prostatic ducts, of which, some can be absorbed into the blood stream, binding to 
antichymotrypsin (ACT) and alpha2-macroglobulin. The intraductal fluid within the 





epithelial layer, basal-cell layer and basement membrane in the normal prostate gland.  
Disrupting the balance, as a result of trauma, disease or cancer can cause the PSA levels 
to increase significantly (Brawley et al, 2007). 
 
Controversies surrounding serum PSA screening include the age to begin and stop 
screening, determination of the threshold value to trigger biopsy (Catalona et al, 2006, 
Hoffman, 2006), screening races who are more prone to developing the cancer,  and if 
other existing diseases will affect the PSA levels.  Some of these issues have remained 
unresolved. As such, overdiagnosis may occur, resulting in unnecessary aggressive 
treatment or invasive procedures, which could affect the patient’s overall well being in 
addition to the possible financial and psychological burden. 
 
It has also been reported that PSA is organ confined rather than cancer specific (Shariat et 
al, 2007). It has also been mentioned that total PSA is not a “classic” tumour marker 
because an increase in level of PSA is not directly correlated with worse stages or grades 
(Shariat et al, 2007). While normal prostatic epithelial cells, hyperplastic and even 
neoplastic prostate epithelial cells all produce PSA, it has also been  reported that the 
highest level of PSA is found in the prostatic transition zone (TZ) of patients with benign 
prostate hyperplasia (BPH) (Shariat et al, 2007). In addition, a number of prostate cancers 
are present in patients with PSA values within normal range (Nishio et al, 2006). There 
have also been reports that PSA levels can decrease with increasing Gleason scores 






There are some groups which suggested lowering the cutoff serum PSA values so that it 
will allow better detection of prostate cancer at an earlier stage (Pelzer et al, 2005, Ross 
et al, 1997). Ross et al also suggested that PSA screening be discontinued at advanced 
age groups since overdetection tends to occur in older age groups (Ross et al, 2005). 
 
Currently, there are no established prognostic immunohistochemical panels for routine 
investigation of prostate cancer found in pathological specimens. An established, reliable 
immunohistochemical panel, like the widely used breast panel of estrogen receptor, 
progesterone receptor and HER2, will allow pathologists and clinicians to treat patients 
more appropriately due to better understanding of the biological nature of the tumour, in 
addition to their use as prognostic factors (Etzioni et al, 2007, Quinn et al, 2000, Shariat 
et al, 2007).  
 
For better understanding of molecular pathogenesis of prostate cancer, markers for 
apoptosis, signal transduction, cell adhesion and cohesion, and angiogenesis in prostate 
cancer will be helpful (Krupski et al, 2000).  Accordingly, androgen receptor (AR), Her-
2/neu, Ki-67 and p53 have been selected to study their expression in prostate cancer, as 
well as neuroendocrine markers chromogranin A, synaptophysin and CD56, and their 
correlation to conventional histological parameters. 
 
1.8 Androgen Receptor (AR) 
The androgen receptor (AR), a member of the nuclear receptor family of ligand activated 





(DBD), and an N-terminal domain (NTD), as well as one or more transactivation 
domains (Agoulnik and Weigel, 2006, Quayle et al, 2007) and a hinge region (Richter et 
al, 1997). The DBD is made up of two zinc finger motifs which are responsible for 
determining the DNA sequences that are recognized by receptors and a carboxyl terminal 
hormone (ligand) binding domain. The carboxyl terminal hormone (ligand) binding 
domain contains activation function 2 (AF-2), an important domain responsible for the 
transcriptional activity of the receptor. The DNA and hormone binding domain are then 
linked by a hinge region. The hinge region contains a nuclear localization signal 
(Agoulnik and Weigel, 2006). 
 
 The AR gene is located on the long arm of chromosome X (Richter et al, 2007) and is 
frequently amplified in androgen-ablation-resistant prostate cancer (Litvinov et al, 
2006 ).AR is important during the development and maintenance of the male organ. AR 
also has transcriptional function, thereby mediating the physiologic effects of androgen. 
This is possible as a result of binding specific DNA sequences known as androgen-
responsive elements (AREs), to trigger the transcription of androgen-responsive genes 
(Richter, 2007). AR are also ligand inducible regulators of gene expression, which can 
alter the protein conformation, allowing binding of coactivator molecules to effect 
androgenic hormonal signaling, hence, mediating transcriptional initiation. 
 
The AR also has amino-terminal poly-glutamine, poly-glycine, and poly-proline repeats, 





tract correlates with prostate cancer risk but the findings are not consistent  (Agoulnik 
and Weigel, 2006). 
 
Normal prostate epithelial cells, almost all primary prostate cancer cells and most 
refractory prostate cancer cells have been reported to express AR (Li et al, 2007).Mutated 
AR proteins have been found in quite a number of androgen-independent prostate cancers 
as well as metastatic tissues. 
 
AR plays a very critical role in AR signaling by regulating cancer cell growth and 
survival. However, it is unclear how prostate cancer cells become androgen insensitive. It 
is probably due to the fact that the tumour cells must either bypass or adapt the AR-
mediated cell growth pathway so that the cells can survive in low androgen concentration 
(Litvinov et al, 2006). It has been found that during prostate tumourigenesis, AR can 
undergo molecular switch, thereby, surpassing proliferation of normal prostatic epithelia 
to directly induce growth of prostate cancer cells, resulting in a gain-of-function changes 
in AR signaling (Li et al, 2007).  Dysregulation of AR co-regulators can also alter AR 
signaling.   
 
1.9 Her-2/neu 
The Her-2 proto oncogene is located on chromosome 17q21 and encodes a 185kd 
transmembrane tyrosine kinase receptor of the epidermal growth factor receptor family, 
more specifically, type 1 tyrosine kinase of ErbB receptor family (Ady et al, 2004, 





referred to as p185neu, Her2 or erbB2. Her-2 is distinct but homologous to other 
members of erbB, possessing intrinsic protein kinase activity. Binding of appropriate 
growth factors to the receptor results in regulation of cell growth, proliferation, 
differentiation through regulation of the receptor tyrosine kinase and triggering signal 
transduction signals. (Montironi et al, 2006) Signal transduction is reportedly involved in 
dimerization and oligomerization. (Berger et al, 2006,Edwards et al, 2006, Freeman, 
2004, Montironi et al, 2006) 
 
Her receptors are involved in the development and maintenance of mammary, cardiac 
and neural tissues besides being implicated in the development and progression of many 
cancers, the most well-known being breast cancer. 
 
Her-2 is an established marker that has been routinely applied for prognostication and 
prediction of response to treatment in breast cancer (Ady et al, 2004, Gu et al, 1996, 
Kominsky et al, 2000). However, its potential as a marker for prostate cancer has not 
been satisfactory as a result of non-standardization of methodologies (Ady et al, 2004, 
Carle et al, 2004, Ross et al, 1997). It has been reported that amplification of the Her-
2/neu gene and /or expression of the protein can be found in  many types of cancers and 
is usually associated with poorer prognosis.  
 
1.10 Ki-67 
Ki-67 is expressed by all active cells at G1, S, G2 and M but not G0 cells (Papadopoulos 





and likelihood of disease progression in a number of tumours, and is related to biological 
aggressiveness and prognosis in several cancers (Bantis et al, 2004, Li et al, 2004).  
 
It has been shown that a high Ki-67 proliferation grade is associated with increased 
prostate cancer recurrence. Positive Ki-67 immunohistochemical staining of prostate 
cancer is believed to be associated with high Gleason score, extension of tumour outside 
of the prostate, and seminal vesicle involvement by tumour (Claudio et al, 2002).  
 
Ki-67 is a huge nuclear non-histone protein, with a molecular weight of 395 kDa (Jamali 
and Chetty, 2008) and is encoded by nearly 30,000 base pairs within the human genome. 
During mitosis, it undergoes phosphorylation and dephosphorylation. Its susceptibility to 
proteases suggests that it is regulated by the proteolytic pathways. Ki-67 is also reported 
to share structural similarities with other proteins involved in cell cycle regulation as Ki-
67 also possesses the forkhead associated domain (FHA) (Brown and Gatter, 2002). 
 
Ki-67 can migrate from the nucleolus to the perichromosomal layer during mitosis. Ki-67 
protein expression varies in intensity throughout the cell cycle – low during G1- and early 
S phase, peaking during mitosis and rapidly decreasing during anaphase and telophase 
(Jamali and Chetty, 2008). 
 
Ki-67 has a very complex and specific localization pattern within the nucleus due to its 
variability during cell cycle. It is associated with the dense fibrillary component (DFC) of 





electron microscopy. Despite vast amounts of information known about Ki-67’s structure, 
regulation and localization, its detailed function remains relatively unknown though it has 
been reported that it is plays a part in serine-threonine phosphorylation during mitosis. Its 




p53 is a tumour suppressor gene and the most commonly mutated gene in more than 50% 
of human cancers (Dong, 2006, Heidenberg et al, 1996, Jin, 2005). Mutations such as 
nucleotide alterations and single point mutations contribute to the mutated p53 (Dong, 
2006, Heidenberg et al, 1996). Allelic loss of the p53 gene on the short arm of 
chromosome 17 at 17p13 is frequently observed in many human tumours, with the 
remaining p53 abnormalities in tumours being point mutations.  Exons 5 to 8 are most 
common for mutations, causing loss of p53 protein-associated cellular functions in 
tumour cells.  Mutated p53 has a much longer half life and accumulates in high levels in 
tumour cell nuclei, and it is this property which allows its expression to be detected on 
immunohistochemical assays (Heidenberg et al, 1996).  
 
p53 gene constitutes about 20kb genomic deoxyribonucleic acid (DNA) located on 
17p13.1. It is made up of 11 exons and is highly conserved since evolution. It is also a 
sequence-specific transcription factor. These exons code for a 393-amino acid nuclear 






p53 plays important roles in DNA damage, hypoxia, oncogene activation (Epstein, 1997), 
cell cycle regulation, autophagy and apoptosis (Claudio et al, 2002, Kominsky et al, 
2000).  The effects of p53 upon activation is dependent on tissue type and context of the 
cells. As such, p53 exerts its tumour suppression in a tissue- and cell-dependent manner 
(Jin, 2005). 
 
As mutated p53 is more commonly expressed in advanced prostate cancer of higher 
tumour stage/grade, metastatic and androgen independent cancers, it is thought not to be 
suitable as an early marker for prostate cancer (Claudio et al, 2002, Heidenberg et al, 
1996, Krupski et al, 2000, Kuczyk et al, 1998). p53 expression is reportedly associated 
with high Gleason score (Kuczyk et al, 1998) and is frequently altered in hormone-
refractory prostate cancer (Lee et al, 2006) with higher expression in cancer than normal 
tissue (Kuczyk et al, 1998).  
 
In response to chemotoxic drugs, accumulation of p53 in cells can occur, hence, 
triggering apoptosis by both transcription-dependent and transcription-independent 
mechanisms in a number of cell types (Mohapatra et al, 2005, Quinn et al, 2000). It can 
act as a transcriptional regulator, including involvement in G1 phase growth arrest of 
cells due to DNA damage as well as regulating spindle check point, centrosome 








1.12 Neuroendocrine Expression and Markers 
Neuroendocrine (NE) cells are the third type of epithelial cells found in benign prostatic 
glands. These cells do not express androgen receptor, and are believed to play a role in 
proliferative and secretory pathways in prostatic glandular epithelium.  They are usually 
scattered among prostatic epithelial cells and are not readily visible on routine light 
microscopy. These cells are terminally differentiated and post mitotic as they come from 
putative stem cells with the basal cell phenotype (Evans et al, 2006). 
 
There may be a link between NE differentiation and tumour progression in prostate 
cancer as Vashchenko reported that androgen-independent clones could regulate the 
proliferation of neighboring cancerous cells, which do not express NE differentiation, to 
secrete NE products in a paracrine fashion (Vaschenko and Abrahamsson, 2005). 
 
In normal prostate glands, NE cells can be found in the normal acini and ducts. The NE 
cells of normal prostate are usually found in the basal cell layer and urothelium, and may 
not possess cytokeratin. The NE cells of normal prostate have both properties of 
endocrine cells and neurons, are therefore, involved in secretory, autocrine and paracrine 
mechanisms (Vaschenko and Abrahamsson, 2005). NE tumours are usually carcinoid like 
neoplasms, carcinoid tumours, atypical carcinoids, small cell carcinoma and large cell NE 
carcinomas (Evans et al, 2006).  
 
Neuroendocrine differentiation in prostatic carcinoma can only be appreciated through 





reported to be the best generic marker for NE differentiation (Sant’agnese, 1998). Other 
preferred NE markers are synaptophysin (Syn) and CD56.  
 
1.13 CD56 
Also known as Leu-19, CD56 is a leukocyte differentiation antigen and a neural cell 
adhesion molecule (NCAM).  
 
CD56 is a differentiation antigen, a cell surface sialoglycoprotein of molecular weight of 
175-185kDa, belonging to the immunoglobulin superfamily (Lanier et al, 1989, 
Lantuejoul et al, 2000). It is expressed on nearly all human natural killer (NK) cells, a 
subset of T lymphocytes and IL-2 activated thymocytes which mediate MHC-unrestricted 
cytotoxicity, but the expression is not restricted to cytotoxic cells.  It is also found to be 
present on CD4+ T helper cell clones, neural tissue and is reported to be involved in 
homotypic adhesion interactions. Many isoforms can be generated by alternative splicing 
and differential polyadenylation (Lanier et al, 1989). 
 
CD 56 is also expressed in neural, neuroectodermal and neuroendocrine (NE) adult 
tissues and tumours.  
 
1.14 Chromogranin A 
Chromogranin A (Chr A) is a member of the secretogranin/chromogranin class of 






The human Chr A is a 439-residue acidic protein, preceded by an 18-residual signal 
peptide, with a highly conserved NH2-terminal and COOH-terminal domains, which 
serves as potential diphasic cleavage sites. The middle portion shows significant 
sequence variation (36%), and this is homologous to porcine pancreastatin (32%). This 
sequence can inhibit glucose-induced insulin secretion. 
 
Chr A has a molecular weight of 48,918kDa, after signal cleavage and if it does not 
undergo any post translational modification. Chr A is found in the matrix of the neuro-
secretory granules, a major integral membrane protein (Konecki et al, 1987). 
 
1.15 Synaptophysin (Syn) 
Synaptophysin (Syn) is an acidic glycoprotein with a molecular weight of 38 000D. It can 
be found the neurons of the brain, spinal cord and retina; adrenal medullary cells, 
pancreatic islet cells and some neuroendocrine neoplasms, including many pancreatic 
islet cell tumours. Syn also behaves as one of the major calcium binding proteins of the 
synaptic vesicle membrane (Chejfec et al, 1987, Schlaf et al, 1996). 
 
Gould (Gould et al, 1986) reported that Syn is present in neuromuscular junctions across 
several mammalian species as demonstrated by immunofluorescence applied on frozen 
sections. Gould (Gould et al, 1986) also reported that Syn is similarly demonstrated by 
immunofluorescence on frozen sections in neoplasms of ganglioneuromas, 






Syn is also found in the entire spectrum of neuroendocrine neoplasms of the neural type, 
from differentiated to  undifferentiated stages, as well as asymptomatic microadenomas 
to adenomas and carcinomas with or without clinical hormonal syndromes, medullary 
thyroid carcinomas, bronchial and gastrointestinal carcinoids and neuroendocrine 
carcinomas of the same sites and in the skin (Chejfec et al, 1987, Schlaf et al, 1996). 
 
1.16 Tissue Microarray (TMA) Technology 
The tissue microarray (TMA) technology was first described by Kononen et al (Kononen 
et al, 1998), whose group also developed the technique. This technology allows rapid 
screening of hundreds to thousands of tumour specimens simultaneously utilizing a 
dedicated tissue arrayer. The size of the sample can range from 0.6mm to 2mm in 
diameter, depending on the size of the cylindrical punch used for the construction. The 
TMA technology is believed to be a modification of the original multitumour tissue 
blocks proposed by Battifora (Battifora, 1986, Tan et al, 2004). 
 
Conventionally, whole sections have been used for screening, which is time consuming 
and costly, and in which immunohistochemical stains can be inconsistent and subjective 
(Battifora, 1986). Use of whole sections will also potentially deplete scarce and precious 
tissues.  
 
High-throughput analysis of candidate biomarkers is now made possible as TMA allows 
hundreds to thousands of tissue samples to be studied on a single slide. This will reduce 





uniformly and under similar conditions. As this involves fewer slides, storage space is 
also reduced. The time taken for the pathologist to review the slides is also very much 
decreased (Battifora, 1986). 
 
Sections from TMA can be used to perform analysis at DNA, RNA and protein levels. 
Since most of the TMA blocks are constructed using formalin-fixed-paraffin-embedded 
(FFPE) tissues, all histotechnological staining which are performed on whole sections, 
can similarly be applied to the TMA sections. 
 
1.17 Scope of Study 
Currently, there are no established prognostic immunohistochemical panels for routine 
investigation of prostate cancer found in the pathological specimens. An established, 
reliable immunohistochemical panel, like the widely used breast panel of estrogen 
receptor, progesterone receptor and Her-2, will allow pathologists and clinicians to treat 
patients more appropriately due to better understanding of the biological nature of the 
tumour, in addition to their use as prognostic factors (Etzioni et al, 2007, Quinn et al, 
2000, Shariat et al, 2007). 
 
For better understanding of molecular pathogenesis of prostate cancer, markers for 
apoptosis, signal transduction, cell adhesion and cohesion, and angiogenesis in prostate 
cancer will be helpful (Krupski et al, 2000). Accordingly, androgen receptor (AR), Her-
2/neu, Ki-67 and p53 have been selected to study their expression in prostate cancer, as 





correlation to conventional histological parameters. The hypothesis of this study is that 
the selected markers – AR, Her-2/neu, Ki-67, p53, chromogranin A, synaptophysin and 
CD56 may have clinicopathological influence in prostate cancer. 
 
The objectives of the study are: 
(1) to evaluate if whether there are any strong associations of the markers selected – AR, 
Her-2/neu, Ki-67, p53, chromogranin A, synaptophysin and CD56 with 
clinicopathological parameters, which can aid in prognosis.  
(2) to determine if there is a strong association between the neuroendocrine markers and 
p53, Ki-67, Her-2/neu and AR. 
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2 MATERIALS AND METHODS 
 
2.1 Patients 
170 cases of acinar adenocarcinoma of the prostate were obtained from 2002 to 2005, 
from patients who had undergone the radical prostatectomy procedure at Singapore 
General Hospital, Singapore. The mean age of the patients was 62.7 years with an age 
range of 37 to 74 years. The ages were calculated as of time of operation.  
 
There were 133 Chinese males (78.2%), 23 Indian males (13.5%), 7 Malay males (4.1%) 
and other males (4.1%) whose ethnicity was not available.  Of these 170 patients, only 
121 had pre-operative PSA levels recorded. 145 patients underwent transrectal ultrasound 
guided prostate needle biopsy (TRUS) while 5 patients underwent transurethral resection 
of the prostate (TURP) prior to radical prostatectomy. There were 8 local males and 11 
foreign males who did not have records of either TRUS or TURP done prior to radical 
prostatectomy and one local male did not have an updated record of the latest TRUS or 
TURP to confirm the diagnosis of acinar adenocarcinoma prior to radical prostatectomy.  
 
Upon performing radical prostatectomy, the prostate gland was submitted for routine 
histological investigation. Histological type, Gleason score, size of tumour, location of 
tumour, extent of tumour were evaluated. Presence or absence or perineural invasion, 
vascular/lymphatic invasion,  presence of tertiary high-grade  prostatic carcinoma, were 
examined. Involvement of tumour at the apex (distal margin), base (proximal margin) and 
any other resection margins was also studied. The pathologic T staging (TxNxMx) 
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system was applied in the overall histological evaluation of the prostate. All radical 
prostatectomy histological evaluation was performed at the Department of Pathology at 
Singapore General Hospital. 
 
This study was approved by the Institutional Review Board (IRB), Singapore General 
Hospital. 
 
2.2 Gross Assessment of Radical Prostatectomy specimen and Preparation of Whole 
Mounts for Histological Evaluation 
The prostatectomy specimens were fixed in fresh buffered formalin overnight. Upon 
complete fixation, the pathologist would first dissect the seminal vesicles before further 
sectioning the prostate specimen at 3 – 5 mm intervals from the apex to the base of the 
prostate.  
 
The radical prostatectomy specimens were weighed and measured cephalocaudally, 
transversely and antero-posteriorly. Both left and right seminal vesicles and vas deferens 
were examined and their lengths measured. The surgical margins were inked with various 
tissue dyes to denote the various orientations.  
  
Upon completion of the gross description, the specimens were processed in a tissue 
processor. 
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Upon completion of tissue processing, the prostate sections were embedded in paraffin 
and sectioned at 4µm on the microtome. The sections were fished onto larger glass slides, 
measuring approximately 2 inches by 3 inches. These sections were then stained by 
routine Hematoxylin and Eosin and evaluated by the pathologists.  
 
2.3 Microscopic Evaluation of the Radical Prostatectomy Hematoxylin and Eosin 
stained sections 
After the sections had been stained by Hematoxylin and Eosin, a pathologist evaluated 
the whole mount preparations of the slides. 
 
Histological type (e.g. acinar adenocarcinoma) was determined. Pathological parameters 
such as Gleason score, size of tumour, presence or absence of perineural/lymphovascular 
invasion were reported. The involvement of  surgical margins (apex, base, and other 
resection margins) was also noted if present. Presence or absence of high-grade prostatic 
intraepithelial neoplasia (HGPIN), intraductal prostatic carcinoma, was also noted. The 
location of the tumor was also determined. 
 
The extent of tumour, which also helped to determine the pathological stage, was defined 
as follows: 
T2: Tumour confined within the prostate 
T2a: Tumour involved one-half of one lobe or less 
T2b: Tumour involved more than one-half of one lobe but not both lobes 
T2c: Tumour involved both lobes 
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T3: Tumour extends through the prostate capsule 
T3a: Unilateral or bilateral extraprostatic extension 
T3b: Tumour invades the seminal vesicles and vas deferens 
T4: Tumour is fixed or invades adjacent structures, besides seminal vesicle.  Other 
structures such as external sphincter, rectum, bladder, levator muscles and/or pelvic wall 
were considered adjacent structures. 
 
2.4 Tissue Microarray (TMA) Construction 
Formalin-fixed, paraffin embedded whole mount preparations of radical prostatectomies 
were evaluated and an area of tumour and an area of benign tissue were marked by a 
pathologist prior to the construction of a tissue microarray block. These benign areas 
from radical prostatectomies represented ‘normal’ comparisons for tumours. 
 
TMA blocks were constructed as previously described. (Kononen et al, 1998, Jensen and 
Hammond, 2001, Rangel, 2002, Jensen, 2003, Tan et al, 2004) Briefly, a “recipient” 
blank paraffin block was made. The “donor” block was the FFPE block, where the tissue 
would be punched to construct the TMA block. Punch sizes were also selected. In this 
study, TMA blocks were constructed using either a punch size with a diameter of 0.6mm 
or 1mm.  Using a dedicated manual tissue arrayer, from Beecher Instruments (Sun Prairie, 
WI), areas of interest from the donor block were punched and inserted into the recipient 
block.   
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A map, indicating the position and identity of the cores, was designed using the Microsoft 
Excel software. Each case had at least duplicates and up to 4 replicates of identical tumor 
tissue cores and benign tissue cores from the same case to ensure adequate sampling of 
the tissue. The TMA blocks were then sectioned at 4µm on a microtome. 
 
2.5 Immunohistochemistry 
4µm thick sections were obtained from the TMA blocks and fished onto charged slides 
(Menzel-Gläser Superfrost Plus, Thermo Scientific, Germany). The sections were heated 
on the hotplate for 20 minutes and deparaffinized from xylene through decreasing grades 
of alcohol.  
 
For sections to be stained with p53, Ki-67, Her-2, Chr A and Syn antibodies, the sections 
were micro-waved for 25 minutes, at 98 ºC in Tris-EDTA, pH8.7.  For staining with AR 
antibodies, the sections underwent pressure cooking for 15 minutes, in Tris-EDTA, 
pH8.7. All microwave and pressure cook procedures were performed on T/T Mega 
Multifunctional Microwave Histoprocessor (Milestone, Italy) especially for use in a 
Histopathology laboratory. After antigen retrieval, the sections were cooled down to 
room temperature and then loaded onto Dako Autostainer. 
 
Peroxidase-blocking solution supplied by Dako, was applied on the slides for 10 minutes 
each. After that, the sections were rinsed with TBS/Tween 20. 300µl optimally diluted 
primary antibody was applied on each slide and incubated for 30 minutes. The primary 
antibodies used were androgen receptor (clone: AR318, Novocastra, USA, 1:35), p53 
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(clone: DO7, Dako, Denmark, 1:70), Ki-67 (clone: Mib-1, Dako, Denmark, 1:300), 
cerbB2 (clone: SP3, Neomarkers, USA, 1:200), Chromogranin A (clone:5H7, Novocastra, 
USA) and Synaptophysin (clone: 27G12, Novocastra, USA). After incubation, the 
sections were again rinsed with TBS/Tween 20. 300µl of labelled polymer with 
horseradish phosphatase (HRP), was applied on each slide for 30 minutes incubation. The 
sections were rinsed with TBS/Tween 20. Freshly prepared diaminobenzidine (DAB) 
chromogen was prepared by mixing the appropriate amount of substrate to the 
chromogen. DAB was applied onto each slide and incubated for 5 minutes. All 
immunostaining procedures were done on the Dako autostainer using the Dako Chemate 
Envision procedure, to ensure that all TMA sections were performed under uniform and 
stable conditions. 
 
After 5 minutes incubation with DAB, the sections were washed with water, 
counterstained in hematoxylin, placed in TBS buffer for 10 seconds, washed with water 
and then dehydrated, cleared and mounted with a mounting medium. 
 
For sections to be stained with CD56 antibodies, the sections underwent deparaffinization, 
antigen retrieval and immunohistochemical staining onboard the Bondmax autostainer. 
Briefly, sections were deparaffinized with commercially available Bond Dewax solution 
two times at 72 ºC and one time at room temperature. After that, the sections were 
hydrated with three changes of alcohol. The sections were then washed with Bond Wash 
solution 4 times. Antigen retrieval was then performed by incubating the sections for 20 
minutes with the commercially available ER2, which was loaded onto the Bondmax. The 
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sections were then washed for 5 or 6 times with the Bond Wash solution prior to 
incubating the peroxide block for 5 minutes. After blocking, the sections were then again 
washed with the Bond wash solution for 3 times. CD56 antibody (clone: NCL56-504, 
Novocastra, USA, 1:200) was then applied onto the sections and incubated for 20 
minutes.  
 
After the incubation, the sections were washed three times with the Bond Wash solution, 
prior to being incubated with the post primary for 8 minutes. The sections were washed 
with the Bond Wash solution and then incubated with the polymer for 8 minutes. The 
sections were again washed with the Bond Wash solution twice, with each step lasting 2 
minutes and then further washed with deionized water. The sections were then incubated 
with the commercially Mixed DAB Refine for 10 minutes and then washed with 
deionized water 3 times. The sections were counterstained with hematoxylin for 4 
minutes and then washed with deionized water, Bond Wash solution and deionized water 
again. 
 
The sections were then further washed under running tap water after being unloaded from 
Bondmax. The sections were then dehydrated, cleared and mount with mounting medium.  
 
Known positive and negative controls for the appropriate antibodies were run together 
with the TMA sections. Details of the antibodies, dilution and antigen retrieval used were 
summarized in Table 2. 
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Table 2 Details of antibodies and dilutions  
 
Antibody  Source  Dilution Pretreatment Method      Clone                                        
 
Androgen  
receptor             Novocastra, USA   1:35                 MW, 15mins, 0.01M Tris   AR318 
                                                                                    EDTA, pH 8.7 
p53gene   Dako, Denmark         1:70                 MW, 15 mins, 0.01M Tris  DO7        
                                                              EDTA, pH 8.7 
Ki-67 antigen    Dako, Denmark         1:300               MW, 15 mins, 0.01M Tris  Mib-1 
                                                                                     EDTA, pH8.7          
Her-2/neu   Neomarkers, USA     1:200               PC, 3 mins, 0.01M Tris       SP3  
                                                                                     EDTA, pH8.7    
CD56                Novocastra, USA   1:200                20mins, ER2,                       CD564 
                                                                                    Onboard Bondmax 
Chromogranin  Novocastra, USA       1:200               MW, 15 mins, 0.01M Tris   5H7        
A                                                                                 EDTA, pH 8.7 
Synaptophysin  Novocastra, USA      1:50                 MW, 15 mins, 0.01M Tris   27G12 
                                                                                    EDTA, pH8.7          
                          
   MW: Microwave   
   PC: Pressure Cook 
   EDTA: Ethylenediaminetetraacetic acid 
 
 
2.6 Scoring of immunohistochemically stained sections 
Nuclear staining of Ki-67, p53 and AR, and membranous staining of Her-2-neu were 
considered positive. Intensities of 0, 1+, 2+ and 3+ indicate no staining, mild staining, 
moderate staining and strong staining respectively. Proportion of cells stained positive 
was indicated in percentages.  
 
Immunoreactive score (IRS) and intensity-percentage score (IPS) were performed for 
those sections immunostained with AR, Ki-67, p53 and Her-2-neu antibodies. IRS was 
calculated as follows: 
(3 x percentage of strongly stained cells) + (2 x percentage of moderately stained cells) + 
(1 x percentage of weakly stained cells) 
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IPS was defined as the product of the percentage of tumour cells of maximum staining 
intensity with percentage of tumour cells stained. 
 
Membranous staining of CD56, cytoplasmic staining of Chr A and Syn were considered 
positive.  
 
Scoring and analysis of the immunostained sections were performed by scanning the 























Figure 2 Immunohistochemical expression of androgen receptor (AR), p53, Ki-67, CD56, 
chromogranin A (Chr A) and synaptophysin (Synap). (A) Positive, nuclear staining of 
AR (B) Negative expression of AR (C) Positive, nuclear staining of p53 (D) Negative 
expression of p53 (E) Positive, nuclear staining of Ki-67 (F) Negative expression of Ki-
67 (G) Positive membranous staining of CD56 (H) Negative expression of CD56 (I) 
Positive cytoplasmic staining of Chr A (J) Negative expression of Chr A (K) Positive, 
cytoplasmic staining of Synap and (L) Negative expression of Synap. All at 100x 
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2.7 Statistical Analysis 
Statistical analysis was performed using SPSS for Windows Version 16. Student T test  
was used for tabulation of mean, median, frequency and range. For correlation studies, 
Chi Square test  was used to study the relationship between each marker and various 
clinicopathological parameters. A p value of < 0.05 was considered statistically 
























3.1 Clinicopathological Parameters Studied 
A total number of 170 radical prostatectomy cases were studied. The clinicopathological 
parameters employed for this study included age, ethinicity, dominant tumour size (cm), 
Gleason score, lymphovascular invasion, perineural invasion, extraprostatic extension, 
associated high grade prostatic intraepithelial neoplasia (HGPIN), seminal vesicle 
invasion and pathological stages as shown in Table 3. These clinicopathological 
parameters were then used in the correlation to study the relationship to the biomarkers. 
Table 3.  Clinicopathologic features of prostate cancer (N=170) 
 
Clinicopathologic parameters                            Number of cases (%)                      
 
Age (Years) (mean 62.7, median 62.5, range 37 to 74 ) 
≤ mean                                                                  85 (50%) 
> mean                                                                  85 (50%) 
 
Ethnicity 
Chinese                                                                133 (78.2%)                                                                            
Malay                                                                      7 (4.1%)                                                                     
Indian                                                                    23 (13.5%)                                                                                    
Others                                                                      7 ( 4.1%)                                                                                 
                                                                    
Dominant Tumor size (cm) (mean 2.6, median 2.4, range 0.3 to 6.6) 
≤ mean                                                                    97 (57.0)                                                                        
> mean                                                                    70 (41.2%)                                                                              
Not accessible                                                           3 (1.8%)         
           
Gleason score 
< 7                                                                           70 (41.2%) 
≥ 7                                                                          100 (58.8%) 
 
Lymphovascular invasion 
Absent                                                                     146 (85.9%)                                                        
Present                                                                       19 (11.2%) 
Not available                                                               3 (2.9%) 
 
Perineural invasion 
Absent                                                                         50 (29.4%) 




Table 3.  Clinicopathologic features of prostate cancer (N=170) (Continuation) 
 
Clinicopathologic parameters                            Number of cases (%)                      
 
Extraprostatic extension   
Absent                                                                       74 (47.6%)                                                    
Present                                                                      89 (52.4%) 
 
Associated HGPIN                                                    
Absent                                                                       33 (19.4%) 
Present                                                                     137 (80.6%) 
 
Seminal vesicle infiltration 
Absent                                                                      153 (90%)                                               
Present                                                                        17 (10%) 
 
Pathologic stage 
T2a                                                                             16 (9.4%) 
T2b                                                                              8 (4.7%) 
T2c                                                                             83 (48.8%) 
T3a                                                                             44 (25.9%)                                                                     
T3b                                                                             17 (710%) 




HGPIN : High grade prostatic intraepithelial neoplasia 
 
Out of 170 patients, there was an equal number of patients whose age was below 62.7 
years old or more than 62.7 years old. The median for the age group was 62.5 and the 
ages ranged from 37 to 74 years old. 
 
There were 133 (78.2%) Chinese, 7 (4.1%) Malays, 23 (13.5%) Indians and 7 (4.1%) 
patients' ethnicity was not indicated. It was noteworthy that there were proportionally 
more Indians diagnosed with prostate cancer than Malays despite the fact that there were 




Out of the 170 cases, there were 97 (41.2%) whereby the dominant tumour size was less 
than the mean of 2.6 cm and 70 (41.2%) cases of tumour size more than 2.6 cm. The 
median of the dominant tumour size was 2.4 cm and the sizes ranged from 0.3 to 6.6 cm.  
 
70 (41.2%) prostate cancers were of Gleason score <7 while 100 (58.8%) prostate 
cancers were of Gleason score ≥7. Figure 2A showed prostate cancer with Gleason score 
of 6 (3+3); note the crowded, discrete glands surrounding the benign gland. Figure 2B 
showed prostate cancer with Gleason score of 7 (4+3). There was predominant Gleason 
pattern 4, comprised of fused, raggedly infiltrating glands, admixed with discrete glands 
of Gleason pattern 3. Figure 2C showed prostate cancer with Gleason score 8 (4+4) – 


















 Figure 3 Prostate cancer with Gleason Sum of (A) 6 (3+3), magnification 200x, (B) 7 
(4+3), magnification 200x and (C)8 (4+4), magnification 100x, as shown in H&E stained 
whole mount sections of radical prostatectomy specimens.  
 
There were 146 85.9% cases whereby there was no lymphovascular invasion, 19 






lymphovascular status was not available. Figure 3A showed a hematoxylin and eosin 
stained section of lymphovascular invasion.  
In 50 (29.4%) cases, there was no perineural invasion seen. Perineural invasion was seen 
in 120 (70.6%) cases. 74 (47.6%) cases evaluated did not show extraprostatic invasion 
while 89 (52.4%) cases had extraprostatic extension. Figure 3B showed presence of 
perineural invasion while figure 3C demonstrated extraprostatic invasion. Note the 




Figure 4 (A) Lymphovascular invasion, 400x magnification, (B) Perineural invasion, 
100x magnification (C)Extraprostatic extension, 400x magnification (D) Seminal vesicle 
invasion, 400x magnification, demonstrated in H&E stained whole mount sections of 









Associated high grade prostatic intraepithelial neoplasia (HGPIN) was seen in 137 
(80.6%) cases while 33 (19.4%) cases did not have HGPIN. Seminal vesicle infiltration 
was seen in 17 (10%) cases while this was absent in 153 (90%) cases. Figure 3D showed 
the presence of seminal vesicle infiltration. 
 
Of the 170 cases studied, there were 16 (9.4%) cases in stage T2a, 8 (4.7%) stage T2b, 83 
(48.8%) stage T2c, 44 (25.9%) stage T3a, 17 (10%) stage T3b.  
 
3.2 Immunoreactivity of the Biomarkers 
All sections were immunohistochemically stained for AR, p53, Ki-67, and her-2/neu. The 
sections were stained in duplicates or triplicates with the appropriate positive and 
negative controls. Table 4 showed the immunohistochemical expression of the various 
antibodies. 
 
Of the 170 cases stained for AR, 94 (57.1%) cases did not have nuclear staining while  57 
(33.5%) showed 1+ intensity staining, 17 (10.0%) showed 2+ intensity staining while 
only 1 (0.6%) showed 3+ intensity staining.  (Table 4) 
 
Table 4. Immunoreactivity of biomarkers  in 170 cases of prostate cancer 
 
Tumour marker                Positive expression______                                           
                               1+                 2+                  3+                Negative 
                                                                                               expression       Total 
Androgen receptor  57 (33.5%)  17 (10.0%)    1 (0.6%)         94 (57.1%)      170 
p53 protein              34 (20.0%)   5 ( 2.9% )      1 (0.6%)        130 (76.5 %)    170 
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Ki-67 antigen         12 (7.1%)    18 (10.6%)    32 (18.8%)     108 (63.5%)      170 
 
Figure 4A showed a TMA section of prostate cancer. Figure 4B showed weak AR 
immunohistochemical expression in normal prostate section. Negative expression of AR 
can also be seen in prostate cancer section as seen in figure 4C. Figure 4D showed a 







Figure 5 Immunohistochemical nuclear expression of androgen receptor in normal and 
cancerous prostate tissues (A) Tissue microarray section of prostate cancer, 50x 
magnification, (B) Weak androgen receptor expression in normal prostate section, 100x 
magnification, (C) Negative expression of androgen receptor in prostate cancer section, 
200x magnification (D) Strongly positive expression of androgen receptor in prostate 






Expression of p53 was not demonstrated in normal prostate tissues by 
immunohistochemistry. Immunohistochemistry only detected mutated p53, which could 
stably accumulate in the cells. Figure 5A showed positive, strong, nuclear 
immunohistochemical expression of p53 in prostate cancer while figure 5B showed 
positive but weak, nuclear immunohistochemical expression of p53. Negative 
membranous expression Her-2/neu in benign prostate tissue and prostate cancer tissue 
was seen in figure 5C and 5D respectively. In this study, almost all prostate tissues, be 





























Figure 6 Immunohistochemical expression of p53 and cerb-B2 in benign and prostate 
cancer tissue, (A) Strong immunohistochemical nuclear expression of p53 in prostate 
cancer tissue, (B) Weak immunohistochemical nuclear expression of p53 in prostate 
cancer tissue, (C) Negative immunohistochemical membranous expression of cerb-B2 in 
benign prostate tissue, (D) Negative immunohistochemical membranous expression of 
cerb-B2 in prostate cancer tissue. Positive expression of p53 was only observed in 
prostate cancer sections while cerb-B2 was not expressed in almost all benign or 
cancerous prostate tissues, all 200x magnification. 
 
 
108 (63.5%) cases showed negative staining for Ki-67; 12 (7.1%) showed 1+ intensity, 
18 (10.6%) 2+ intensity, 32 (18.8%) 3+ intensity staining. (Table 4) Figure 6A showed 
negative expression of nuclear  Ki-67 in prostate cancer tissue while figure 6B showed 





expression of nuclear Ki-67 was depicted in figures 6C and 6D respectively. Figure 6E 
showed 3 intensities of nuclear Ki-67 expression in a prostate cancer tissue – 1+, 2+ and 

























Figure 7 Immunohistochemical expression of nuclear Ki-67 in benign prostate tissue and 
prostate cancer tissue. (A) Negative expression of Ki-67 in prostate cancer tissue, 200x 
magnification, (B)Negative  immunohistochemical nuclear staining of Ki-67 in benign 
prostate tissue, 100x magnification, (C) Weak immunohistochemical staining of nuclear 
Ki-67 in prostate cancer tumor, 200x magnification (D) Strong, positive 
immunohistochemical staining of nuclear Ki-67 in prostate cancer, 400x magnification, 
and (E) 1+, 2+ and 3+ immunohistochemical staining intensity of nuclear  Ki-67 in 








3.3 Correlation of Androgen Receptor Expression and Clinicopathological 
Parameters 
Table 5 summarized the findings of the relationship of the clinicopathological parameters 
and androgen receptor (AR) while Figure 4 showed the various AR staining intensity. 
 
Out of the 83 cases whereby the patients’ ages were less than the mean of 62.7 years, 45 
(54.2%) cases showed negative staining for AR and 38 (45.8%) showed positive staining. 
There were 84 cases whereby the patients’ ages were more than the mean of 62.7 years. 
Among these 84 cases, 47 (56.0%) cases were negatively stained for AR while 37 (44.0%) 
were positively stained for AR. A p value of 0.555 was obtained.  
 
Among 131 Chinese men, 75 (57.3%) prostate cancers were negatively stained for AR 
while 56 (42.7%) were positively stained for AR. Among the 7 Malay cases, 3 (42.9%) 
and 4 (57.1%) were negatively and positively stained for AR respectively. As for the 22 
Indian cases, 14 (63.6%) and 8 (36.4%) were negatively and positively stained for AR 
respectively. The remaining 2 cases whereby the ethnicity was indicated as “others”, the 
sections stained positive for AR. A p value of 0.969 was obtained. 
  
There were 96 cases where the dominant tumour size was less than the mean of 2.6cm of 
which there were equal numbers of negatively and positively stained cases. Of the 68 
cases where tumour size was more than the mean of 2.6 cm, 41 (60.3%) and 27 (39.7%) 




Of the 69 cases which reported Gleason scores of less than 7, 42 (60.9%) and 27 (39.1%) 
were negatively and positively stained for AR respectively. As for the 98 cases which had 
reported Gleason scores more than 7, 50 (51.0%) and 28 (49.0%) were negatively and 
positively stained for AR respectively.  A p value of 0.190 was obtained. 
 
143 cases did not have lymphovascular invasion, of which 79 (55.2%) and 64 (44.8%) 
were negatively and positively stained for AR respectively. 19 cases showed 
lymphovascular invasion: 11 (57.9%) and 8 (42.1%) cases showed negative and positive 
AR expression respectively.  A p value of 0.843 was obtained.  
 
50 cases did not have perineural invasion, of which, 33 (66.0%) and 17 (34.0%) were 
negatively and positively stained for AR respectively. Of the 117 cases which showed 
perineural invasion, 59 (50.4%) and 58 (49.6%) cases showed negative and positive AR 
expression respectively. A p value of 0.007 was obtained. 
 
Of the 95 cases where there was absence of extraprostatic extension, 54 (56.8%) and 41 
(43.2%) cases showed negative and positive AR expression respectively. There were 64 
cases which had extraprostatic extension of which, 34 (53.1%) and 30 (46.9%) showed 
negative and positive expression of AR respectively.  A p value of 0.054 was obtained. 
 
Of the 33 cases which did not have associated HGPIN, 19 (57.6% and 14 (42.4%) were 
negatively and positively expressed for AR respectively. For the 134 cases which had 
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associated HGPIN, 73 (54.5%) and 61 (45.5%) were negatively and positively expressed 
for AR respectively. A p of value 0.63 was obtained. 
 
Seminal vesicle infiltration was absent in 148 cases, of which, 78 (52.7%) and 70 (47.3%) 
showed negative and positive expression of AR respectively. 17 cases were reported to 
have seminal infiltration; 12 (70.6%) and 5 (29.4%) had negative and positive AR 
expression respectively. A p value of 0.328 was obtained. 
 
For stage T2a, 7 (43.8%) and 9 (56.2%) showed negative and positive AR expression 
respectively. 4(57.1%) and 3 (42.9%) T2b cases were negatively and positively stained 
for AR respectively.  Of the 81 T2c cases, 47 (58.0%) and 34 (42.0%) showed negative 
and positive AR expression respectively. As for the 44 T3a cases, 21 (47.7%) and 23 
(52.2%) were negative and positive for AR expression respectively. 17 T3b cases were 
seen, and 11 (64.7%) and 6 (35.3% ) cases were negative and positive for AR expression 



















Table 5. Correlation of androgen receptor (AR) expression with clinicopathological   
              parameters 
Clinicopathologic parameters      AR Negativity       AR Positivity     Total    p Value 
 
Age (Years) (mean 62.7, median 62.5, range 37 to 74  )                                 0.555 
≤ mean                                              45 (54.2%)            38 (45.8%)           83                                                                        
> mean                                              47 (56.0%)            37 (44.0%)           84                    
                                                                
Ethnicity                                                                                                                  0.969 
Chinese                                             75 (57.3%)            56 (42.7%)           131                                                        
Malay                                                  3 (42.9%)              4 (57.1%)               7                      
Indian                                                 14 (63.6%)             8 (36.4%)             22                    
Others                                                   0 (0.0%)              2  (100%)                2 
                                                          
Dominant Tumor size (cm) (mean 2.6, median 2.4, range 0.3 to 6.6)                0.262 
≤ mean                                                  48 (50.0%)           48 (50.0%)           96                         
> mean                                                  41 (60.3%)           27 (39.7%)           68                     
                                                                  
Gleason score                                                                                                         0.190 
< 7                                                     42 (60.9%)            27 (39.1%)            69                         
≥ 7                                                     50 (51.0%)            28 (49.0%)            98   
                                                       
Lymphovascular invasion                                                                                     0.843 
Absent                                               79 (55.2%)           64 (44.8%)            143                          
Present                                              11 (57.9%)            8 (42.1%)               19    
                                                               
Perineural invasion                                                                                               0.007 
Absent                                              33 (66.0%)            17 (34.0%)                50                                            
Present                                             59 (50.4%)             58 (49.6%)              117      
                                          
Extraprostatic extension                                                                                       0.054 
Absent                                              54 (64.3%)             30(35.7%)                 84                      
Present                                             34  (45.3%)             41(54.7%)                 75  
                                                         
Seminal vesicle infiltration                                                                                     0.328 
Absent                                             78 (52.7%)                 70 (47.3%)            148                      
Present                                             12 (70.6%)                  5 (29.4%)              17 
                                       
Pathologic stage                                                                                                       0.844 
T2a                                                  7 (43.8%)                      9 (56.2%)          16                           
T2b                                                  4 (57.1%)                      3 (42.9%)            7               
T2c                                                 47 (58.0%)                    34 (42.0%)          81                  
T3a                                                 21 (47.7%)                    23 (52.2%)          44 





3.4 Correlation of p53 protein with clinicopathological parameters 
The correlation between p53 and the various clinicopathological parameters was shown 
in Table 6.  
 
There were 85 cases whereby the age was less than 62.7 years; negative and positive p53 
expression was seen in 66 (77.6%) and 19 (22.4%) respectively. Of the 84 cases which 
consisted of males who were more than 62.7 years, 63 (75.0%) and 21 (25.0%) showed 
negative and positive p53 expression respectively. A p value of 0.936 was obtained 
 
There were 131 Chinese, of which 97 (73.6%) and 35 (26.6%) had negative and positive 
p53 staining respectively. Of the 7 Malay cases, 6 (85.7%) and 1 (14.3%) showed 
negative and positive staining respectively. 23 Indian cases reported showed that 20 
(87.0%) and 3 (13.0%) stained negatively and positively for p53. 2 cases of other ethnic 
groups showed positive staining for p53. A p value of 0.076 was obtained. 
 
96 cases had dominant tumour size less than the mean of 2.6 cm; 69 (71.9%) and 27 
(28.1%) showed negative and positive p53 staining respectively. 70 cases had dominant 
tumour sizes more than the mean of 2.6 cm; 57 (81.4%) and 13 (18.6%) showed negative 
and positive staining respectively. A p value of 0.168 was obtained. 
 
Of the 69 cases which showed Gleason score of less than 7, 57(82.6%) and 12 (17.4%) 
showed negative and positive staining for p53 respectively. 100 cases had Gleason score 
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more than 7 – 72 (72%) and 28 (28%) were p53 negatively and positively demonstrated 
respectively. A p value of 0.076 was obtained. 
 
There were 145 cases without lymphovascular invasion; 108 (74.4%) and 37 (25.5) were 
negatively and positively stained for p53 respectively. Of the 19 reported lymphovascular 
invasion cases, 16 (84.2%) and 3 (15.8%) were negatively and positively stained for p53 
respectively. A p value of 0.281 was obtained.  
 
39 (79.6%) and 10 (20.4%) cases were corresponding negatively and positively stained 
for p53 in 49 cases with no perineural invasion. 120 cases were reported to have 
perineural invasion, of which 90 (75.0%)  and 30 (25.0%) were negative and positive for 
p53 respectively. A p value of 0.614 was obtained. 
 
Extraprostatic extension was not seen in 95 cases – 70 (73.7%) stained negative for p53 
and 25 (26.3%) stained positive for p53. 65 cases were associated with extraprostatic 
extension of which 52 (80.0%) and 13 (20.0%) stained negative and positive respectively 
for p53. A p value of 0.740 was obtained.  
 
33 cases did not have HGPIN reported, of which 20 (60.6%) and 13 (39.4%) showed 
negative and positive p53 expression respectively. Out of the 136 HGPIN cases, 109 
(80.1%) and 27 (19.9%) showed negative and positive p53 expression respectively. A 




150 cases did not have seminal vesicle infiltration; 116 (77.3%) and 34 (22.7%) showed 
negative and positive expression of p53 correspondingly.  Of the 17 cases with seminal 
vesicle infiltration, 11 (63.7%) ad 6 (35.3%) were respectively negative and positive for 
p53. A p value of 0.302 was obtained. 
 
For the 16 T2a cases, 11 (68.8%) and 5 (31.2%) were respectively negative and positive 
for p53. 8 T2b cases showed 3 (37.5%) and 5 (62.5%) negative and positive p53 
expression respectively. Similarly, out of the 82 T2c cases, 62 (75.6%) negative and 20 
(24.4%) instances of  positive p53 expression was seen. 44 T3a cases evaluated showed 
41 (93.2%) and 3 (6.8%) stained negatively and positively for p53 respectively. 17 T3b 
cases evaluated showed 11 (64.7%) negative  and 6 (35.3%)  positive p53 staining. A p 
value of 0.250 was obtained. 
 
Table 6. Correlation of p53 protein immunoreactivity with clinicopathological  
               parameters 
Clinicopathologic parameters    p53 Negativity    p53 Positivity      Total     p Value 
 
Age (Years) (mean 62.7, median 62.5, range 37 to 74  )                              0.936                 
≤ 62.7                                             66 (77.6%)            19 (22.4%)           85                                                                        
> 62.7                                             63 (75.0%)            21 (25.0%)           84                    
                                                                
Ethnicity                                                                                                                0.076 
Chinese                                            97 (73.5%)            35 (26.6%)          131                                          
Malay                                               6 (85.7%)               1(14.3%)               7                      
Indian                                               20 (87.0%)              3(13.0%)             23       
Others                                               2 (100.0%)             0 (0.0%)                2        
                                                          
Dominant Tumor size  (cm) (mean 2.6, median 2.4, range 0.3 to 6.6)               0.168          
≤ 2.6                                                69 (71.9%)             27 (28.1%)           96                                     
> 2.6                                                57 (81.4%)             13 (18.6%)           70                      
                                                                  
Gleason score                                                                                                        0.076 
< 7                                                    57 (82.6%)            12 (17.4%)            69                                      
≥ 7                                                    72 (72.0%)            28 (28.0%)           100     
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 Table 6.  Correlation of p53 protein immunoreactivity with clinicopathological  
                Parameters (continued) 
 
Clinicopathologic parameters    p53 Negativity    p53 Positivity      Total     p Value 
                
Lymphovascular invasion                                                                                    0.281                                                                     
Absent                                              108 (74.4%)         37 (25.5%)            145                            
Present                                               16  (84.2%)          3  (15.8%)              19     
                                   
Perineural invasion                                                                                               0.614                                                           
Absent                                              39 (79.6%)           10 (20.4%)               49                         
Present                                              90 (75.0%)           30 (25.0%)             120 
                                                                     
Extraprostatic extension                                                                                       0.740 
Absent                                              70 (73.7%)           25 (26.3%)               95                         
Present                                             52 (80.0%)           13 (20.0%)                65       
                                                                    
Seminal vesicle infiltration                                                                                    0.302 
Absent                                                 116 (77.3%)      34 (22.7%)               150        
Present                                                  11 (64.7%)        6  (35.3%)                17 
                                                            
Pathologic stage                                                                                                     0.250 
T2a                                                      11 (68.8%)        5 (31.2%)                  16 
T2b                                                        3 (37.5%)        5 (62.5%)                   8     
T2c                                                      62 (75.6%)        20(24.4%)                 82           
T3a                                                      41 (93.2%)         3 (6.8%)                   44        





3.5 Correlation of Ki-67 antigen immunohistochemical expression with 
clinicopathological parameters 
The correlation between Ki-67 and the various clinicopathological parameters was 
summarized in Table 7. There were equal numbers of patients of less than 62.7 years and 
more than 62.7 years. 54 (63.5%) and 31 (36.5%) stained negatively and positively for 





133 Chinese cases showed 86 (64.7%) and 47 (35.3%) to be stained negatively and 
positively for Ki-67 correspondingly. Of the 7 Malay cases, 3 (42.9%) and 5 (57.1%) 
showed negative and positive staining pattern respectively. 16 (69.6%) and 7 (30.4%) 
Indian cases had negative and positive staining for Ki-67 respectively. 2 cases belonging 
to other ethnic groups had a negative and positive Ki-67 staining.  A p value of 0.201 was 
obtained. 
 
Of the 97 cases of dominant tumour size less than mean of 2.6cm, 64 (66.0%) and 33 
(34.0%) were negatively and positively stained for Ki-67 respectively. 70 cases had 
dominant tumour size more than the mean of 2.6cm, of which 42 (60.0%) and 28 (40.0%) 
were negatively and positively Ki-67 stained respectively. A p value of 0.201 was 
obtained.  
 
70 cases had Gleason score less than 7, of which 47 (67.1%) and 23 (32.9%) were 
negatively and positively stained for Ki-67 respectively. Of the 100 cases which had 
Gleason score more than or equal to 7, 61 (61%) and 39 (39%) were negatively and 
positively stained for Ki-67 respectively. A p value of 0.376 was obtained. 
 
146 cases did not show lymphovascular invasion; 91(62.3%) and 55 (37.7%) were 
negatively and positively stained for Ki-67 respectively. 19 cases showed 
lymphovascular invasion, of which 13 (68.4%) and 6 (31.6%) were negatively and 




Of the 50 cases reported which showed absence of perineural invasion, 31 (62%) and 19 
(38%) were negatively and positively stained for Ki-67 respectively. 120 cases were 
shown to have perineural invasion and 77(64.2%) and 43(35.8%) were negatively and 
positively stained for Ki-67 respectively. A p value of 0.715 was obtained. 
 
96 cases did not show extraprostatic extension – 61(63.5%) and 35(36.5%) stained for 
Ki-67 negatively and positively respectively. 65 cases showed extraprostatic extension, 
43 (66.2%) and 22 (33.8%) were negatively and positively stained for Ki-67 respectively. 
A p value of 0.546 was obtained. 
 
151 cases were reported to show absence of seminal vesicle infiltration – 93 (61.1%) and 
58 (38.4%) stained negatively and positively respectively for Ki-67. 17 cases showed 
seminal vesicle infiltration, 13 (76.5%) and 4 (23.5%) were negatively and positively 
stained for Ki-67 respectively. A p value of 0.591 was obtained. 
 
Of the 16 T2a cases, 8(50%) and 8(50%) showed negative and positive Ki-67 expression 
respectively. 3(37.5%) and 5(62.5%) of the 8 cases of T2b stage were negative and 
positive for Ki-67 expression respectively. There were 83 T2c cases, of which 58 (69.9%) 
and 23 (30.1%) were negative and positive for Ki-67 respectively. There were 44 T3a 
cases and 25(56.8%) and 19(43.2%) were negative and positive for Ki-67 
respectively.The rest of the 17 T3b cases showed 14(82.4%) and 3(17.6%) negatively and 





Table 7.Correlation of Ki-67 antigen immunoexpression with clinicopathological  
              Parameters 
Clinicopathologic parameters     Ki-67 Negativity   Ki-67 Positivity   Total    p                                 
                                                                                                                                 Value                 
 
Age (Years)(mean 62.7, median 62.5, range 37 to 74)                                        0.407                 
≤ 62.7                                                54 (63.5%)            31 (36.5%)           85                          
> 62.7                                                54 (56.0%)            31 (36.5%)           85                    
                                                                
Ethnicity                                                                                                                   0.977 
Chinese                                             86 (64.7%)            47 (35.3%)          133                                                           
Malay                                                 3  (42.9%)              4 (57.1%)              7                       
Indian                                                16 (69.6%)              7 (30.4%)            23        
Others                                                 1  (50.0%)              1 (50.0%)              2                  
 
Dominant Tumor size (cm) (mean 2.6, median 2.4, range 0.3 to 6.6)                 0.201         
≤ 2.6                                                  64 (66.0%)            33 (34.0%)           97                      
> 2.6                                                  42 (60.0%)            28 (40.0%)           70                     
                                                                  
Gleason score                                                                                                           0.067 
< 7                                                     47 (67.1%)            23 (32.9%)            70                                      
≥ 7                                                     61 (61.0%)            39 (39.0%)          100         
                                                                    
Lymphovascular invasion                                                                                       0.376 
Absent                                             91 (62.3%)              55 (37.7%)          146                           
Present                                            13 (68.4%)               6 (31.6%)              19                    
                                                                          
Perineural invasion                                                                                                   0.715 
Absent                                            31 (62.0%)                19 (38.0%)           50                         
Present                                            77 (64.2%)                43 (35.8%)          120 
                                                                      
Extraprostatic extension                                                                                          0.546 
Absent                                            61 (63.5%)                 35 (36.5%)           96 
Present                                            43 (66.2%)                 22 (33.8%)           65                 
                                                                                                                  
Seminal vesicle infiltration                                                                                        0.591 
Absent                                                   93 (61.6%)       58 (38.4%)             151                      
Present                                                  13 (76.5%)         4 (23.5%)               17 
                                                            
Pathologic stage                                                                                                 
T2a                                                        8 (50.0%)        8 (50.0%)                16          0.073    
T2b                                                        3 (37.5%)        5 (62.5%)                  8     
T2c                                                       58 (69.9%)      25 (30.1%)                83        
T3a                                                       25 (56.8%)      19 (43.2%)                44      




3.6 Correlation of Clinicopathological Parameters and Biomarkers 
AR, p53 and Ki-67 intensity of staining, percentage of cells stained, IPS and IRS were 
statistically analysed against the clinicopathological parameters as shown in Table 8. 
 
High (Gleason score ≥7) versus low Gleason scores (Gleason score <7) were statistically 
significant when compared with AR IRS (p=0.039), indicating that AR IRS is positively 
correlated with Gleason score of ≥ 7.  Gleason score, in general, was also statistically 
significantly positively correlated to p53 staining intensity (p=0.018), indicating that 
stronger p53 immunostaining is often associated with increasing Gleason score. Vascular 
invasion was inversely correlated to AR IRS. Perineural invasion was inversely 
correlated to AR intensity, AR percentage, AR IPS and AR IRS with p values 0.007, 
0.003, 0.003 and 0.004 respectively. Extraprostatic extension was also inversely 
correlated to AR IRS (p=0.035).    
 
Lymph node involvement was also inversely correlated to AR intensity, AR percentage, 
AR IPS, AR IRS with p values 0.007, 0.005, 0.002 and 0.002 respectively. On the other 
hand, preoperative PSA level was statistically significantly associated with Ki-67 


















































































































































































































































































































































































































































































































































































































































































































































































3.7 Correlation of Androgen Receptor (AR) and p53, AR and Ki-67, p53 and Ki-67 
AR IPS and p53 IPS were statistically significantly correlated with each other, with p 
value of 0.041, showing a direct correlation. Direct correlation was also seen between AR 
IRS and p53 IRS (p=0.015), p53 intensity and Ki-67 intensity (p=0.027). AR IRS and Ki-


















































































































































































































































































































































































































































3.8 Immunoreactivity of Neuroendocrine Biomarkers 
All sections were immunohistochemically stained for Chr A, Syn and CD56. The sections 
were stained in duplicates or triplicates with the appropriate positive and negative 
controls. Table 10 showed the immunohistochemical expression of the antibodies used 
for the study of neuroendocrine expression. 
 
Table 10. Immunoreactivity of neuroendocrine markers  in 170 cases of prostate        
                 cancer 
 
Tumour marker          Positive Expression           Negative Expression        Total 
CD56                                    32 (18.8%)                          138 (81.2%)                 170  
Chromogranin A                  19 (11.2%)                           151 (88.8%)                 170                           
Synaptophysin                      58 (34.1%)                          112 (65.9%)                  170    
 
 
Of the 170 cases stained for CD56, 138 (81.2%) did not have any cytoplasmic staining 
while 32 (18.8%) showed positive cytoplasmic expression.  Figure 7A showed   moderate, 
positive, membranous staining of CD56 in prostate cancer tissue while figure 7B showed 







Figure 8 Immunohistochemical expression of CD56 (NCAM) in prostate cancer tissue 
(A) Moderate, positive membranous expression of CD56 in prostate cancer tissue, 400x 




19 (11.2%) showed positive Chr A cytoplasmic staining, while 151 (88.8%) did not show 
any cytoplasmic staining. Figure 8A showed a TMA section of prostate cancer tissue 
being positively stained for Chr A. Weak, positive cytoplasmic expression in prostate 
cancer section was seen in figure 8B while figure 8C showed strong, positive cytoplasmic 














Figure 9 Immunohistochemical expression of Chromogranin A (Chr A) in prostate 
cancer tissue. (A) TMA section of prostate tissue showing cytoplasmic expression of Chr 
A, 50x magnification (B) Focal positive cytoplasmic expression of Chr A, 400x 
magnification and (C) Strong positive cytoplasmic expression of Chr A in prostate cancer 
sections, 400x magnification.  
 
 
58 (34.1%) showed positive Syn cytoplasmic staining while the remaining 112 (65.9%) 
showed no staining. Figure 9A showed positive, cytoplasmic reactivity in benign 
epithelium of prostate. Positive cytoplasmic Syn expression was seen in prostate cancer, 
as shown in figure 9B, figure 9C showed positive, diffuse, cytoplasmic expression of Syn 









Figure 10 Immunohistochemical cytoplasmic expression of  Synaptopysin (Syn) in 
benign prostate tissue and prostate cancer tissue. (A) Cytoplasmic Syn expression in 
benign epithelium of prostate, 400x magnification, (B) Positive cytoplasmic Syn 
expression in prostate cancer tissue, 200x magnification, (C) Diffuse positive cytoplasmic 
expression of Syn, 100x magnification and (D) Scattered, cytoplasmic expression of Syn 











3.9 Correlation of CD56 Expression and Clinicopathological Parameters 
The correlation between CD56 and various clinicopathological parameters was shown in 
Table 11.  
 
Of the 85 cases where the ages were less than the mean age of 62.7 years, 68 (80.0%) 
cases stained negative for CD56 while 17 (20.0%) cases stained positive for CD56. Of 
the remaining 85 cases, where the ages were more than the mean age of 62.7 years, 70 
(82.4%) stained negative for CD56 while the remaining 15 (17.6%) cases stained positive 
for CD56.  A p value of 0.97 was obtained. 
 
There were 133 Chinese, of which 108 (81.2%) and 25 (18.8%) had negative and positive 
CD56 expression respectively. Of the 7 Malays, all were negative for CD56 expression. 
Of the 23 Indians, 18 (78.3%) and 5 (21.7%) were negatively and positively stained for 
CD56 respectively. 2 cases of which the ethnicity was not indicated, none were positively 
stained for CD56. A p value of 0.848 was obtained. 
 
There were 97 cases whereby the mean dominant tumour size was less than 2.6 cm; of 
which 79 (81.4%) and 18 (18.6%) cases were negative and positive for CD56 
respectively. The rest of the 70 cases which were more than the mean of 2.6 cm, saw 56 
(80.0%) and 14 (20.0%) cases which were negative and positive for CD56 respectively. 




70 cases had Gleason score less than 7, of which 57 (81.4%) and 13 (18.6%) were 
negative and positive for CD56 respectively. The rest of the 100 cases, which had 
Gleason score more than 7, 81 (81.0%) and 19 (19.0%) cases were negative and positive 
for CD56 respectively. A p value of 0.944 was obtained. 
 
There were 146 cases, whereby there was no lymphovascular invasion seen. Of these 
cases, 119 (81.5%) and 27 (18.5%) were negative and positive for CD56 respectively. 19 
cases showed lymphovascular invasion – 14 (73.7%) and 5 (26.3%) were negative and 
positive for CD56 respectively. A p value of 0.420 was obtained. 
 
There were 120 cases reported to have perineural invasion present, of which 97 (80.0%)  
and 23 (19.2%)  cases were negative and positive for CD56 respectively. 50 cases did not 
have perineural invasion seen, of which 41  (82.0%) and 9 (18.0%) were negative and 
positive for CD56 respectively. A p value of 0.860 was obtained. 
 
65 cases showed extraprostatic extension, of which 52 (80.0%) and 13 (42.0%) showed 
negative and positive immunoreactivity for CD56 respectively. 96 cases did not show 
extraprostatic extension, of which 78 (81.3%) and 18 (18.7%) were negative and positive 
for CD56 respectively. A p value of 0.845 was obtained. 
 
17 cases showed seminal vesicle infiltration – 13 (76.5%) and 4 (23.5%) cases were 
negative and positive for CD56 respectively. 151 cases were reported to show absence of 
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seminal infiltration – 123 (81.5%) and 28 (18.5%) cases were negative and positive for 
CD56 respectively. A p value of 0.622 was obtained. 
 
There were 16 T2a cases, of which, 11 (68.8%) and 5 (31.2%) were negative and positive 
for CD56 respectively. 8 cases were T2b, of which 6 (75.0%) and 2 (25.0%) were 
negative and positive for CD56 respectively. 83 cases were of T2c stage, of which 70 
(84.3%) and 13 (15.7%) were negative and positive for CD56 respectively. Of the 44 T3a 
cases, 36 (81.8%) and 8 (18.2%) were negative and positive for CD56 respectively. There 
were 17 T3b cases, of which 13 (76.5%) and 4(23.5%) cases were negative and positive 
for CD56 respectively. A  p value of 0.566 was obtained. 
 
Table 11. Correlation of CD56 expression with clinicopathological   
                 parameters 
Clinicopathologic parameters      CD56 Negativity  CD56 Positivity Total        p      
                                                                                                                                   Value       
 
Age (Years) (mean 62.7, median 62.5, range 37 to 74)                                       0.97 
≤ mean                                              68 (80.0%)            17 (20.0%)           85                                                                        
> mean                                              70 (82.4%)            15 (17.6%)           85                    
                                                                
Ethnicity                                                                                                                  0.848 
Chinese                                             108 (81.2%)             25 (18.8%)         133                                                        
Malay                                                   7 (100.0%)              0 (0%)                 7                      
Indian                                                  18 (78.3%)               5 (21.7%)           23                    
Others                                                   2 (100.0%)              0 (0%)                 2 
                                                          
Dominant Tumor size (cm) (mean 2.6, median 2.4, range 0.3 to 6.6)                0.816 
≤ mean                                                  79 (81.4%)           18 (18.6%)           97                         
> mean                                                  56 (80.0%)           14 (20.0%)           70                     
                                                                  
Gleason score                                                                                                         0.944 
< 7                                                     57 (81.4%)            13 (18.6%)            70                                                      
≥ 7                                                     81 (81.0%)            19 (19.0%)            100   





Table 11. Correlation of CD56 expression with clinicopathological   
                 Parameters (continued) 
 
 Clinicopathologic parameters     CD56 Negativity     CD56 Positivity  Total    p              
                                                                                                                                    Value 
Lymphovascular invasion                                                                                     0.420 
Present                                               14 (73.7%)               5 (26.3%)             19                      
Absent                                              119 (81.5%)            27 (18.5%)           146    
                                                               
Perineural invasion                                                                                               0.860 
Present                                              97 (80.8%)            23 (19.2%)             120                        
Absent                                              41 (82.0%)              9 (18.0%)               50    
                                          
Extraprostatic extension                                                                                       0.845 
Present                                              52 (80.0%)              13(42.0%)             65                      
Absent                                               78 (81.3%)              18(18.7%)             96           
                                                                        
Seminal vesicle infiltration                                                                                     0.622 
Present                                              13 (76.5%)                   4 (23.5%)            17                    
Absent                                             123 (81.5%)                 28 (18.5%)          151 
                                     
Pathologic stage                                                                                                       0.566 
T2a                                                  11 (68.8 %)                      5 (31.2%)          16                           
T2b                                                    6 (75.0%)                       2 (25.0%)            8               
T2c                                                  70 (84.3%)                      13 (15.7%)         83                  
T3a                                                  36 (81.8%)                        8 (18.2%)         44 




3.10 Correlation of Chromogranin A (Chr A) Expression and Clinicopathological 
Parameters 
Table 12 showed the expression of Chr A in relation to the various clinicopathological 
parameters studied. 
 
There were 85 cases whereby the patient’s mean ages were less than the mean of 62.7 
years, of which, 75 (88.2%) and 10 (11.8%) showed negative and positive 
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immunoreactive Chr A by immunohistochemistry respectively. The other half, whereby 
the ages were more than the mean of 62.7 years saw 76 (89.4%) and 9 (10.6%) being 
negative and positive for Chr A respectively. A p value of 0.809 was obtained. 
 
There were 133 Chinese, of which 120 (90.2%) and 13 (9.8%) showed negative and 
positive Chr A expression respectively. All 7 Malays showed negative Chr A expression 
while of the 23 Indians, 20 (87.0%) and 3 (13.0%) showed negative and positive Chr A 
expression respectively. Of the 2 other cases, whereby the ethnicity was unavailable, 1 
(50%) was negative for Chr A expression while the other (50%) showed positive Chr A 
expression. A p value of 0.329 was obtained. 
 
There were 97 cases which were reported to have dominant tumour size less than the 
mean of 2.6 cm, of which 83 (85.6%) and 14 (14.4%) were negative and positive for Chr 
A respectively. As for the rest of the 70 cases which had sizes of more than the mean of 
2.6cm, 65 (92.9%) and 5 (7.1%) showed negative and positive Chr A expression 
respectively. A p value of 0.145 was obtained. 
 
70 cases were reported to have Gleason score less than 7, of which 62 (88.6%) and 8 
(11.4%) were negative and positive for Chr A expression respectively. Of the remaining 
100 cases whereby the Gleason score was more than 7, 89 (89%) and 11 (11%) were 




There were 19 cases which were reported to show presence of lymphovascular invasion, 
of which 17 (89.5%) and 2 (10.5%) were negative and positive for Chr A expression 
respectively. Of the remaining 146 cases which were reported to show absence of 
lymphovascular invasion, 129 (88.4%) and 17 (11.6%) were negative and positive for 
Chr A expression respectively. A p value of 0.887 was obtained. 
 
120 cases were found to show presence of perineural invasion, of which 63 (52.5%) and 
57 (46.5%) were negative and positive for Chr A expression respectively. Of the 50 cases 
which showed absence of perineural invasion, 28 (56.0%) and 22 (44.0%) were negative 
and positive for Chr A expression respectively. A p value of 0.755 was obtained. 
 
65 cases were found to show extraprostatic extension, of which 59 (90.8%) and 6 (9.2%) 
were negative and positive for Chr A expression respectively. Of the 96 cases which did 
not show presence of extraprostatic extension, 83 (86.5%) and 13 (13.5%) were negative 
and positive for Chr A respectively. A p value of 0.409 was obtained. 
 
17 cases showed presence of seminal vesicle infiltration, of which 16 (94.1%) and 1 
(5.9%) were negative and positive for Chr A expression respectively. 151 cases showed 
absence of seminal vesicle infiltration, of which 133 (88.1%) and 18 (10.9%) were 
negative and positive for Chr A respectively. A p value of 0.459 was obtained. 
 
There were 11 T2A cases, of which 11 (68.7%) and 5 (31.3%) were negative and positive 
for Chr A expression respectively. All 8 T2b cases were negative for Chr A expression. 
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Of the 84 T2c cases, 74 (89.2%) and 9 (10.8%) were negative and positive for Chr A 
respectively. Of the 44 T3a cases, 41 (93.2%) and 3 (6.8%) showed negative and positive 
Chr A expression respectively. There were 17 T3b cases, of which 15 (88.2%) and 2 




Table 12. Correlation of Chromogranin A (Chr A) expression with  
                 clinicopathological parameters 
Clinicopathologic parameters      Chr A Negativity  Chr A Positivity Total      p      
                                                                                                                                   Value       
Age (Years) (mean 62.7, median 62.5, range 37 to 74  )                                     0.809 
≤ mean                                              75 (88.2%)            10 (11.8%)           85                                                                        
> mean                                              76 (89.4%)              9 (10.6%)           85                    
                                                                
Ethnicity                                                                                                                  0.329 
Chinese                                             120 (90.2%)            13 (9.8%)           133                                                        
Malay                                                  7   (100%)               0 (0%)                 7                      
Indian                                                 20 (87.0%)               3 (13.0%)           23                    
Others                                                  1 (50.0%)               1 (50.0%)             2 
                                                          
Dominant Tumor size (cm) (mean 2.6, median 2.4, range 0.3 to 6.6)                0.145 
≤ mean                                                  83 (85.6%)           14 (14.4%)          97                          
> mean                                                  65 (92.9%)             5 (7.1%)            70                     
                                                                  
Gleason score                                                                                                         0.931 
< 7                                                     62 (88.6%)             8 (11.4%)               70                                                      
≥ 7                                                     89 (89.0%)            11 (11.0%)             100 
                                                       
Lymphovascular invasion                                                                                     0.887 
Present                                               17 (89.5%)              2 (10.5%)              19                      
Absent                                             129 (88.4%)           17 (11.6%)            146     
                                                               
Perineural invasion                                                                                               0.755 
Present                                              63 (52.5%)             57 (47.5%)              120                                            
Absent                                              28 (56.0%)              22 (44.0%)               50      
                                          
Extraprostatic extension                                                                                       0.409 
Present                                              59 (90.8%)               6 ( 9.2%)              65                      
Absent                                              83 (86.5%)              13 (13.5%)            96           
                                                         
Seminal vesicle infiltration                                                                                     0.459 
Present                                               16 (94.1%)                   1 (5.9%)            17                      
Absent                                             133 (88.1%)                 18 (10.9%)         151 
                
Pathologic stage                                                                                                       0.125 
T2a                                                  11 (68.7%)                      5 (31.3%)          16                           
T2b                                                    8 (100%)                        0 (0.0%)             8               
T2c                                                   74 (89.2%)                      9 (10.8%)          83                  
T3a                                                   41 (93.2%)                      3 ( 6.8%)           44 





3.11 Correlation of Synaptophysin (Syn) Expression and Clinicopathological             
Parameters 
Table 13 summarized the findings between synaptophysin (Syn) expression in relation to 
the various clinicopathological parameters studied.  
 
Of the 85 cases, whereby the mean age was less than 62.7 years, 58 (68.2%) and 27 
(31.8%) were negative and positive for Syn expression respectively. For the remaining 85 
cases, 54 (63.5%) and 27(36.5%) cases were negative and positive for Syn respectively. 
A p value of 0.520 was obtained. 
 
There were 133 Chinese, of which 85 (63.0%) and 48 (36.4%) were negative and positive 
for Syn respectively. Of the 7 Malays, 6 (85.7%) and 1 (13.7%) showed negative and 
positive Syn expression respectively. There were also 23 Indians, of which 18 (78.3%) 
and 5 (21.7%) were negative and positive for Syn respectively. Of the 2 cases whereby 
the ethnicity was not indicated, 1 (50%) was negative while the other (50%) was positive 
for Syn respectively. A p value of 0.222 was obtained. 
 
There were 97 cases whereby the dominant tumor size was less than the mean of 2.6cm – 
52 (74.3%) and 18 (25.7%) cases were negative and positive for Syn respectively. For the 
rest of the 100 cases, 60 (60.0%) and 40 (40.0%) were negative and positive for Syn 




19 cases were reported to show presence of lymphovascular invasion, of which 11 
(57.9%) and 8 (42.1%)  were negative and positive for Syn expression respectively. 146 
cases were reported to show absence of lymphovascular invasion, of which 97 (66.4%) 
and 49 (33.6%) were negative and positive for Syn respectively. A p value of 0.464 was 
obtained. 
 
There were 120 cases which were reported to show presence of perineural invasion – 76 
(63.3%) and 44 (36.7%) were negative and positive for Syn expression respectively. 50 
cases did not show perineural invasion, of which, 36 (72.0%) and 14 (28.0%) were 
negative and positive for Syn expression respectively. A p value of 0.280 was obtained. 
 
65 cases showed presence of extraprostatic extension, of which 45 (69.2%) and 20 
(30.8%) were negative and positive for Syn respectively. 61 cases showed absence of 
extraprostatic extension, of which 61 (63.5%) and 35 (36.6%) showed negative and 
positive Syn expression respectively. A p value of 0.458 was obtained. 
 
17 cases were found to have seminal vesicle infiltration, of which 11 (64.7%) and 6 
(35.3%) were negative and positive for Syn respectively. 151 cases did not show seminal 
vesicle infiltration, of which, 100 (66.2%) and 51 (33.8%) were negative and positive for 
Syn respectively. 
 
There were 16 T2a cases, of which 10 (62.5%) and 6 (37.5%) were negative and positive 
for Syn expression respectively. Of the 8 T2b cases, 5 (62.5%) and 3 (37.5%) were 
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negative and positive for Syn expression respectively. 83 T2c cases were found – 55 
(66.3%) and 28 (33.7%) were negative and positive for Syn respectively. There were 44 
T3a cases reported, of which 31 (70.5%) and 13 (29.5%) were negative and positive for 
Syn respectively. Of the 17 T3b cases, 11 (64.8%) and 6 (35.2%) cases were negative and 
positive for Syn expression respectively. A p value of 0.727 was obtained.
Results 
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Table 13. Correlation of Synaptophysin (Syn) expression with clinicopathological      
parameters 
Clinicopathologic parameters      Syn Negativity      Syn Positivity Total      p      
                                                                                                                               Value        
Age (Years) (mean 62.7, median 62.5, range 37 to 74  )                                     0.520 
≤ mean                                              58 (68.2%)            27 (31.8%)           85                            
> mean                                              54 (63.5%)            31 (36.5%)           85                    
                                                                
Ethnicity                                                                                                                  0.222 
Chinese                                             85 (63.0%)            48 (36.4%)           133                                                        
Malay                                                  6 (85.7%)              1 (13.7%)               7                      
Indian                                                 18 (78.3%)             5 (21.7%)              23                    
Others                                                   1 (50.0%)             1 (50.0%)              2 
                                                          
Dominant Tumor size (cm) (mean 2.6, median 2.4, range 0.3 to 6.6)                 0.307 
≤ mean                                                  67 (69.1%)           30 (30.9%)           97                         
> mean                                                  43 (61.4%)           27 (38.6%)           70                     
                                                                  
Gleason score                                                                                                           0.054 
< 7                                                     52 (74.3%)            18 (25.7%)            70                                                      
≥ 7                                                     60 (60.0%)            40 (40.0%)            100   
                                                       
Lymphovascular invasion                                                                                      0.464 
Present                                               11 (57.9%)              8 (42.1%)              19                      
Absent                                                97 (66.4%)             49(33.6%)            146    
                                                               
Perineural invasion                                                                                                 0.280 
Present                                             76 (63.3%)              44 (36.7%)              120                                            
Absent                                              36 (72.0%)             14 (28.0%)                50      
                                          
Extraprostatic extension                                                                                        0.458 
Present                                              45 (69.2%)               20 (30.8%)             65                     
Absent                                              61 (63.5%)               35 (36.5%)             96           
                                                         
Seminal vesicle infiltration                                                                                     0.901 
Present                                              11 (64.7%)                 6 (35.3%)              17                    
Absent                                             100 (66.2%)               51(33.8%)            151 
                                                      
Pathologic stage                                                                                                        0.727 
T2a                                                  10 (62.5%)                      6 (37.5%)          16                           
T2b                                                   5 (62.5%)                       3 (37.5%)            8               
T2c                                                  55 (66.3%)                    28 (33.7%)          83                  
T3a                                                  31 (70.5%)                    13 (29.5%)          44 




3.12 Correlation of Neuroendocrine Differentiation (NED) and Clinicopathological 
Parameters 
Table 14 summarized the findings between NED in relation to the various 
clinicopathological parameters studied. Presence of NED is defined by any positive 
immunohistochemical expression seen, be it with any one marker or a combination of one, 
two or even three markers studied, and in this case, CD56, chromogranin A and 
synaptophysin. 
   
Of the 85 cases, whereby the mean age was less than the mean of 62.7 years, 47 (55.3%) 
showed absence of NED while 38 (44.7%) showed presence of NED. There were also 85 
cases whereby the mean age was more than the mean of 62.7 years, of which 44 (51.8%) 
and 41 (48.2%) showed absence and presence of NED respectively. A p value of 0.647 
was obtained. 
 
There were 133 Chinese, of which 70(52.6%) an 63(47.4%) showed absence and 
presence of NED respectively. Of the 7 Malays, 6 (85.7%) and 1 (14.3%) showed 
absence and presence of NED respectively. 14 (60.9%) and 9 (39.1%) of the 23 Indians 
showed absence and presence of NED respectively. For the other two cases, whereby the 
ethnicity was unavailable, 1 (50.0%) showed absence of NED while the other showed 
presence of NED. A p value of 0.363 was obtained. 
 
Out of the 97 cases whereby the dominant tumor size was less than the mean of 2.6cm, 
54 (55.7%) showed no NED while 43 (44.3%) expressed NED. There were 70 cases 
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whereby the dominant tumor size was more than the mean of 2.6cm – 35 (50.0%) did not 
show NED while another 35 (50.0%) showed NED. A p value of 0.472 was obtained. 
 
70 cases had Gleason score less than the mean of 7, of which 42 (60.0%) showed no 
NED while 43 (44.3%) showed NED. 100 cases had Gleason score more than the mean 
of 7, of which 49 (49.0%) showed absence of NED while 51 (51.0%) showed presence of 
NED. A p value of 0.159 was obtained.  
 
There were 19 cases where lymphovascular invasion was present. 9 (47.4%) cases did not 
show NED while 10(52.6%) showed NED. Of the 146 cases whereby there were no 
lymphovascular invasion seen, 78 (53.4%) and 68 (46.6%) showed absence and presence 
of NED respectively. A p value of 0.621 was obtained. 
 
120 cases showed perineural invasion; 63 (52.5%) did not have NED while 57 (47.5%) 
had NED. Perineural invasion was not seen in 50 cases, of which, 28 (56.0%) and 22 
(44.0%) showed absence and presence of NED respectively. A p value of 0.679 was 
obtained. 
 
Extraprostatic extension was seen in 65 cases – 35 (53.8%) did not have NED while 30 
(46.2%) showed NED. There were also 96 cases, whereby extraprostatic extension was 
not observed, of which, 51 (53.1%) did not have NED while 45 (46.9%) had NED. A p 
value of 0.929 was obtained. 
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Seminal vesicle infiltration was seen in 17 cases – 8 (471%) and 9 (52.9%) showed 
absence and presence of NED respectively. 151 cases did not have seminal vesicle 
infiltration reported, of which, 82 (54.3%) did not show NED while 69 (45.7%) showed 
NED. A p value of 0.573 was obtained. 
 
There were 16 T2a cases, of which 10 (62.5%) did not show NED while 9 (37.5%) had 
NED. Of the 8 T2b cases, 4 (50.0%) did not show NED while the other half had NED. 83 
cases were classified as T2c, of which 47 (56.7%) and 36 (43.3%) showed absence and 
presence of NED respectively. Of the 44 T3a cases, 25 (45.5%) did not show NED while 
19 (54.5%) showed NED. Of the 17 T3b cases, 8 (47.1%) and 9 (52.9%) showed absence 
and presence of NED respectively. A p value of 0.809 was obtained. 
 
Table  14. Correlation of neuroendocrine differentiation (NED) with  
clinicopathological parameters 
Clinicopathologic parameters                          NED                               Total      p      
                                                           Absent                  Present                             Value           
 
Age (Years) (mean 62.7, median 62.5, range 37 to 74)                                       0.647 
≤ mean                                              47 (55.3%)            38 (44.7%)           85                                                                        
> mean                                              44 (51.8%)            41 (48.2%)           85                    
                                                                
Ethnicity                                                                                                                  0.363 
Chinese                                              70 (52.6%)          63 (47.4%)           133                            
Malay                                                  6 (85.7%)            1 (14.3%)               7                      
Indian                                                 14 (60.9%)           9 (39.1%)             23                    
Others                                                  1  (50%)              1  (50%)                 2 
                                                          
Dominant Tumor size (cm) (mean 2.6, median 2.4, range 0.3 to 6.6)               0.472 
≤ mean                                                54 (55.7%)           43 (44.3%)           97                                                     
> mean                                                35 (50.0%)           35 (50.0%)           70                     
                                                                  
Gleason score                                                                                                         0.159 
< 7                                                      42 (60.0%)            28 (40.0%)            70                                                      
≥ 7                                                      49 (49.0%)            51 (51.0%)            100   
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Table 14. Correlation of neuroendocrine differentiation (NED) with 
clinicopathological parameters (continued) 
 
Clinicopathologic parameters                          NED                               Total      p      
                                                              Absent                  Present                       Value   
Lymphovascular invasion                                                                                      0.621 
Present                                                  9 (47.4%)             10 (52.6%)              19                                                                    
Absent                                                 78 (53.4%)             68 (46.6%)           146    
                                                               
Perineural invasion                                                                                                 0.679 
Present                                                63 (52.5%)              57 (47.5%)            120                                            
Absent                                                 28 (56.0%)              22 (44.0%)            50      
                                          
Extraprostatic extension                                                                                         0.929 
Present                                                35 (53.8%)               30 (46.2%)             65                     
Absent                                                 51 (53.1%)               45 (46.9%)            96           
                                                         
Seminal vesicle infiltration                                                                                      0.573 
Present                                                 8 (47.1%)                 9 (52.9%)              17                         
Absent                                                82 (54.3%)               69 (45.7%)            151 
                                       
Pathologic stage                                                                                                        0.809 
T2a                                                  10 (62.5%)                      9 (37.5%)          16                           
T2b                                                   4 (50.0%)                       4 (50.0%)            8               
T2c                                                  47 (56.7%)                    36 (43.3%)          83                  
T3a                                                  25 (45.5%)                     19 (54.5%)         44 




3.13 Correlation of Neuroendocrine Differentiation (NED) and AR, Ki-67 and p53 
Immunohistochemical Expression 
There were 95 cases whereby AR immunohistochemical expression was absent, of which 
52 (54.7%) did not show NED while 43 (45.3%) showed NED. Of the 75 cases whereby 
the immunohistochemical expression of AR was positive, 39 (52.0%) and 36 (48.0%) 
showed absence and presence of NED respectively. A p value of 0.729 was obtained. 
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130 cases demonstrated negative immunohistochemical expression of p53, 75 (57.7%) 
cases did not show NED while 55 (42.3%) showed NED. There were also 40 cases of 
positive immunohistochemical expression of p53, where 16 (40.0%) and 24 (60.0%) 
showed absence and presence of NED respectively. A p value of 0.05 was obtained. 
 
108 cases were immunohistochemically negative for Ki-67, of which 67 (62.0%) and 41 
(38.0%) showed absence and presence of NED respectively. 62 cases were 
immunohistochemically positive for p53, of which 24 (38.7%) and 38 (61.3%) were 
absent and present for NED respectively. A p value of 0.003 was obtained.    
 
Table 15. Correlation of neuroendocrine differentiation (NED) and AR, Ki-67 and 
p53 immunohistochemical expression 
  NED  
 Biomarkers Absent 
 
 Present Total p Values 
 AR Status  0.724 
 Negative 52 (54.7%) 43 (45.3) 95   
 Positive 39 (52.0%) 36 (48.0%) 75   
 p53 Status  0.050 
 Negative 75 (57.7%) 55 (42.3%) 130   
 Positive 16 (40.0%) 24 (60.0%) 40   
 Ki-67 Status  0.003 
 Negative 67 (62.0%) 41 (38.0%) 108   











































Prostate cancer is the third commonest cancer among Singaporean men. Currently, 
prostate cancer is detected by using serum PSA levels, and then confirmed by the gold 
standard diagnostic method of trans-rectal ultrasound (TRUS) guided needle core 
biopsies (Fradet, 2009). Patients with localized curable prostate cancer may be offered 
radical prostatectomy to completely remove the prostate, with removal of surrounding 
lymph nodes in some cases. After surgery, patients will have their serum PSA monitored 
periodically to ensure that there is no further rise in serum PSA levels as a rise in serum 
PSA level after radical prostatectomy indicates biochemical recurrence.  
 
However, as the level of serum PSA is affected by age, race and weight (Botchorishvili et 
al, 2009), there is a need to explore other molecular biomarkers, which could be used to 
more accurately prognosticate and predict the outcome of treatment as well as the risk of 
biochemical recurrence.  
 
Currently, prognosis depends on preoperative serum PSA, histological findings of TRUS 
biopsies and clinicopathological parameters of radical prostatectomy specimens that 
include assessment of the presence or absence lymphovascular invasion, perineural 





In order to better understand the progression of prostate cancer, and also to improve the 
current diagnosis of aggressive cancer, proliferation marker Ki-67, androgen receptor 
(AR), tumour suppressor as well as apoptosis-related marker – p53, signal transduction-
related marker Her-2-neu, and neuroendocrine markers – chromogranin A (Chr A), 
synaptophysin (Syn) and CD56 were evaluted to determine their usefulness in predicting 
the aggressiveness of prostate cancer. 
 
4.2 Clinicopathological Features of Prostate Cancer 
170 radical prostatectomy specimens were obtained from male patients, who underwent 
the procedure at Singapore General Hospital, Singapore from 2002 to 2005.   
 
Clinicopathological features – pre-operative and post-operative seum PSA levels, 
dominant tumour size (cm), Gleason score, lymphovascular invasion, perineural invasion, 
extraprostatic invasion, seminal vesicle infiltration and pathological stage are used to 
study prostate cancer. The presence of associated HGPIN was also included in the study. 
These parameters are currently most commonly used to prognosticate the treatment 
outcome as well as to predict disease aggressiveness and biochemical recurrence after 
radical prostatectomy has been performed on prostate cancer patients. 
 
As reported by Srigley (Srigley, 2006), these parameters provide vital information for 
patient care. Srigley also suggested information pertaining to these parameters to be 
presented to the urologists as well as other clinicians for their understanding and 




According to the classification of prognostic factors developed at the consensus meetings 
sponsored by the College of American Pathologists (CAP) in 1994 and 1999, three 
categories of classification of prognostic factors could be applied for better understanding 
of prostate cancer biology (Srigley, 2006). 
 
Prognostic factors of category 1 are those which had been established to be useful in 
patient care and had been widely published. Gleason score, pathologic stage and margin 
status belong to category 1 prognostic factors (Srigley, 2006). 
 
The Gleason grading used is based on “The 2005 International Society of Urological 
Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Cancer” 
published by American Journal of Surgical Pathology in 2005 (Epstein, 2005). In this 
consensus, it is important to note that the Gleason grading system may face challenges on 
needle biopsies due to the limited sampling, as compared to radical prostatectomy 
specimens where the entire prostate is available for pathologic evaluation.  
 
The pathologic staging based on the “2002 TNM Staging of Prostatic Adenocarcinoma”, 
incorporated the term ‘extraprostatic extension’ which replaced terminology of 
extracapsular extension, capsular penetration and capsular perforation. Proposal for this 
change in terminology is due to the recognition that the prostate does not have a well-
defined capsule like that of the renal capsule (Srigley, 2006). Also, in this new staging 




either one or both seminal vesicles”. (Srigley, 2006)  All these changes have been 
incorporated in this study. 
 
Involvement of surgical margins is often associated with more adverse outcomes. Apex 
(distal margin), base (proximal margin) and other resection margins are being evaluated 
and reported in histopathological reports. In this study, the status of the margins in 
relation to biological markers was not evaluated while the immunohistochemical 
expression of selected biologic markers with clinicopathological parameters of prostate 
cancer was being investigated and the status of surgical margins in relation to operative 
technique were being compared.  
 
Prognostic factors of category 2 are those which are potential candidates, as proven by 
published works, but require further validation studies (Srigley, 2006). Tumour volume is 
an example of such prognostic factor falling in this category. Tumour volume has been 
reported to be correlated with Gleason score, pathologic stage, margin status and disease 
aggressiveness following radical prostatectomy, however, studies have shown that 
tumour volume cannot be used an independent prognostic factor, but needed to be used 
together with other parameters (Carvalhal et al, 2010, Guzzo et al, 2007, Sirgley, 2006). 
 
Statistically significant findings to show correlation of tumour volume with intensity of 
cells stained positive, percentage of cells stained positive, IPS and IRS was not found. 
This is probably due to lack of standardization in methods of assessing tumour volume 




inspection of percentage of radical prostatectomy specimen involved by cancer, 
measuring the diameter of the largest tumour nodule, number of whole mount blocks 
showing cancer involvement and totaling the number of whole mount blocks, using 
Humphrey and Voilmer grid-square analysis (Shi et al, 2001). The lack of standardization 
of assessing tumour volume in radical prostatectomy specimens will render tumour 
volume to be less favourable as a candidate for prognostication (Shi et al, 2001). Tumour 
volume is still being indicated in histological findings and reports but cannot be used 
independently to predict or prognosticate disease progression and therapy to be 
administered.   
 
There were 3 cases whereby the tumour volume was not available. Also, there was no 
consensus publication available to indicate the mean threshold of tumour volume to be of 
significance in terms of predictive or prognostic ability (Srigley 2006).  Instead, the mean 
was calculated based on the cohort for this study, rather than an established mean from 
literature. 
 
Category 3 prognostic factors are those which have been shown to be of prognostic value, 
but there are not enough data to support their claim. Perineural invasion is an example of 
category 3 prognostic factor. In this study, perineural invasion was found to be 
statistically significantly correlated with AR. Expression of AR has been associated with 
poor prognosis and decreased time to biochemical recurrence (Agoulnik et al, 2006, 
Litvinov et al, 2006, Richter et al, 2007 ) Perineural invasion is a common finding, 




invasion is also reported to be associated with extraprostatic extension, which is an 
indication of worse prognosis. Unfortunately, like tumour volume, perineural invasion 
cannot be used as an independent prognostic factor.  
 
While the pathological study of whole mount preparations of radical prostatectomy 
specimens remains the current gold standard, application of molecular biomarkers will 
not only aid in prognostication of disease and prediction of therapy outcome, these 
markers will also aid in better understanding of disease progression.  
 
4.3 Correlation of Her-2/neu Expression with Clinicopathological Parameters 
Overexpression of Her-2/neu in prostate cancer has been intensively studied (Berger et al, 
2006, Carle et al, 2004, Edwards et al, 2006, Freeman et al, 2004, Kominsky et al, 2000, 
Mellinhoff et al, 2004, Montironi et al, 2006, Nishio et al, 2006, Shariat et al, 2007, Shi 
et al, 2001). The effects of Her-2/neu expression is well documented in breast cancer.  In 
breast cancer, it has been demonstrated that Her-2/neu overexpression inversely 
correlates with the estrogen receptor level and therefore can be used to predict 
antiestrogen therapy outcome, that is, whether there will be resistance to the therapy (Shi 
et al, 2001).  
 
Overexpression of Her-2/neu protein has been reported to be due to activation of the HER 
family, which can occur as a result of receptor overexpression, mutational activation, 
increased growth factor concentration, and gene amplification (Edwards et al, 2006, Shi 




protein kinase and the  PI3K/Akt signaling cascades to be activated, it is believed this 
will lead to increased cell proliferation and decreased apoptosis. There is therefore, 
suggestion that these activation triggers will lead to modifications of the HER family, 
associated with tumourigenesis and cancer progression (Edwards et al, 2006).  
 
The association between Her-2/neu and AR and AR signaling pathways has been studied 
by various groups (Berger et al, 2006, Edwards et al, 2006,Mellinhoff et al, 2004, 
Ricciardelli et al, 2008, Wen et al 2000). Ricciardelli (Ricciardelli et al, 2008) reported 
that expression of Her-2/neu and AR in prostate cancer could alter the signaling pathways 
and thereby be associated with metastatic prostate cancer. Their study found no 
association between high Her-2/neu and AR in immunohistochemical staining with either 
Gleason scores or pre-operative serum PSA levels. They also demonstrated that AR could 
be activated in in vitro systems in the absence of native ligands, growth factors, cytokines, 
protein kinase-A (PKA) and even in overly expressed Her-2/neu. Ricciardelli’s groups 
demonstrated their findings by overexpressing Her-2/neu in androgen-independent 
LNCaP cell line, which showed growth of the cell line and activation of transcription of 
PSA without androgen. They suggested that Her-2/neu was able to activated MAP kinase 
and Atk pathways, thereby allowing prostate cancer cells survival and growth without 
androgens (Shi et al, 2001). 
 
Edwards et al (Edwards et al, 2006) observed that increase in Her-2/neu expression in 
prostate cancer is associated with decreased biochemical recurrence time, which 




decreased apoptosis, hence, more aggressive disease progression. They (Edwards et al, 
2006) had also reported that PI3K/Atk cascade played a role in prostate cancer 
progression, but unlike Ricciardelli et al (Ricciardelli et al, 2008) Edwards et al further 
suggested that PI3K/Akt pathway was activated by EGFRvIII rather than AR but they did 
not study the role of AR in association with the HER family in their article (Edwards et al, 
2006).  
 
Berger (Berger et al, 2006) reported that downregulation of AR resulted in increased 
expression of Her-2/neu. They also demonstrated that induction and activation of Her-
2/neu could result from AR inactivation. Activating signaling pathways such as the 
PI3K/Atk via phosphorylation of Her-2/neu through heterodimerization with other erb 
members, could confer survival to prostate cancer cells.  
 
Mellinghoff (Mellinghoff et al, 2004) also found that the Atk pathway is involved in AR 
function. They reported that Her-2/neu signals are important for optimal AR function, 
enhanced binding of AR to androgen-responsive elements (AREs) and that at low 
androgen concentration, Her-2/neu dependent signaling is important. However, they were 
unclear about how Her-2/ERBB3 kinase pathways could modulate AR  function.  
 
Mellinghoff  (Mellinghoff et al, 2004) and Wen (Wen et al, 2000) reported that the 
involvement of Her-2/neu in prostate cancer to be controversial. Both groups had 




pathway, but also via the Akt independent pathway. They also reported that Her-2/neu 
can stabilize AR and enhance binding of AR to AREs.  
 
However, there was no association found of Her-2/neu with all clinicopathological 
parameters studied as well as all the biomarkers. This is because all the sections were 
either negatively stained or very weakly positively stained to be meaningfully considered 
for correlations in the study. Other groups attempting to find the association of Her-2/neu 
with prostate cancer disease progression have also faced similar difficulty (Ricciardelli et 
al, 2008, Signoretti et al, 2000). 
 
Ricciardelli et al (Ricciardelli et al, 2008)  and Edwards et al (Edwards et al, 2006) 
suggested that the discrepant findings could be due to the use different monoclonal or 
polyclonal antibodies, different antigen retrieval methods used in immunohistochemistry, 
variable primary antibody concentrations, different antibody clones applied, different 
methods of assessment (for instance, in situ hybridization and immunohistochemistry). 
The heterogenicity of prostate cancer could also contribute to their controversial findings 
((Ricciardelli et al, 2008, Edwards et al, 2006).  
 
In addition, the type of samples used for the study could also affect the outcome. Animal 
models, cell lines, bone marrow, blood samples, radical prostatectomy specimens, TRUS 
specimens, cohort of patients selected, were just some examples of variation in sample 





A combination of different types of assessments, different types of samples and wider 
selection of patient cohort will allow better understanding of Her-2/neu in prostate cancer. 
Since AR function was reported to be affected by Her-2/neu, PI3K and Atk pathways, 
more extensive studies should be carried out not only in vivo or in vitro, but also on 
patient samples. 
 
4.4 Correlation of Androgen Receptor (AR) Expression with Clinicopathological 
Parameters 
As shown in Table 5, of all the clinicopathological parameters studied, only perineural 
invasion was statistically significant at p=0.007, showing a positive correlation between 
AR and perineural invasion. Srigley has reported that there are studies showing positive 
correlation between perineural invasion and disease progression, therefore, 
overexpression of AR could mean a worse prognosis. 
 
Extraprostatic extension was almost statistically significant, with p=0.054 (Table 8), an 
inverse correlation suggesting a trend indicating that AR expression was associated with 
worse prognosis. There was no correlation of the AR and other clinical parameters – age, 
ethnicity, tumour size, Gleason score, lymphovascular invasion, seminal vesicle 
infiltration and pathological stage, as indicated by statistically insignificant p values. This 
finding was similar to that of Ricciardelli (Ricciardelli et al, 2008) who also did not find 
an association between AR and Gleason score and even preoperative PSA serum levels. 
Mori (Mori et al, 2008) also did not find association between intensity and positivity of 




AR IRS was positively correlated to Gleason score, indicating a worse prognosis (Table 8) 
as this meant that AR IRS was associated with increasing Gleason score. Unusually, 
perineural invasion was inversely correlated to AR intensity, AR percentage, AR IPS and 
AR IRS as shown by p values of 0.007, 0.003, 0.003, 0.004 respectively. AR IRS was 
inversely correlated to vascular invasion and extraprostatic extension. This discrepant 
finding was also reported by other groups, (Alers et al, 2000, Lévesque et al, 2009, Mori 
et al, 2008) who reported that they did not find clear association between overexpression 
of AR and several clinical and pathological parameters, and even time to biochemical 
recurrence. Levesque (Lévesque et al, 2009) reported that there was no significant 
difference in AR expression in benign, HGPIN and prostatic adenocarcinoma. They also 
suggested that cytoplasmic localization of AR might play a role in disease progression, 
but their observation was based on cell lines rather than on human prostate cancer tissues.  
They also demonstrated AR expression in nuclei and cytoplasm by 
immunohistochemistry. However, when they demonstrated AR expression by in situ  
hybridization, they found AR to be localized exclusively in nuclei, more prominently in 
metastatic than localized prostate cancers.  They did not find AR in cytoplasm of 
noncancerous acini or benign biopsies 
 
Such conflicting observations could be due to the quality of the biopsies as a result of 
different fixation time, the type and clone of antibody used, type of staining applied (that 
is, whether immunohistochemistry or in situ hybridization), comparison of AR expression 





4.5 Correlation of p53 Expression with Clinicopathological Parameters 
There are many studies showing p53 to be a robust prognostic marker for prostate cancer 
(Erbersdobler et al, 2002, Heidenberg et al, 1996, Kuczyk et al, 1998, Petrescu et al, 
2006, Singh et al, Uzoaru et al, 1998).  
 
Mutation of p53 is the commonest genetic alteration in malignant cells. Missense 
mutation, inactivating p53 by interacting with viral and cellular oncoprotein, can lead to 
p53 mutation. Loss of wild type p53 functions can lead to uncontrolled regulation of cell 
cycle checkpoints and DNA replication, defective or inefficient DNA repair, favouring 
tumorigenesis, all of which can lead to accumulation of mutated p53 in the cells. Mutated 
p53 is more stable than wild type p53, hence, mutated p53 can be detected by 
immunohistochemistry. 
 
Uzoaru (Uzoaru et al, 1998)  reported that mutated p53 was less frequently expressed in 
prostate cancer than other cancers, hence, the reliability of p53 as a prognostic marker in 
prostate cancer had been questioned. Uzoaru (Uzoaru et al, 1998)  also reported that 
overexpression of p53 was associated with more aggressive disease. Petrescu reported 
that while p53 was a dependable prognostic marker, there are also other studies 
suggesting otherwise (Petrescu et al, 2006).  
 
Petresch reported that p53 had been associated with high pathological grade, DNA 




prognostic marker, when combined with currently existing clinicopathological 
parameters, expression of p53 could still prognosticate the severity of the cancer. 
There was no statistically significant correlation between p53 and clinicopathological 
parameters. Only ethnicity and Gleason score showed a trend towards statistical 
significance, with p = 0.076, a positive correlation indicating that overexpression of p53 
was associated with Chinese ethnicity and a higher Gleason score. (Table 8) 
 
Gleason score was again found to be positively correlated with p53 intensity (Table 8), 
indicating that overexpression of p53 was associated with increasing Gleason score, also 
suggesting that it could predict a worse outcome. 
 
4.6 Correlation of Ki-67 Expression with Clinicopathological Parameters 
Ki-67 has been reported to be of great prognostic value in many cancers. While the exact 
function of Ki-67 was unclear, it is usually known to be essential in cell proliferation, and 
is tightly controlled and regulated. As a proliferation marker, measurement of Ki-67 is a 
very useful prognostic, diagnostic and research tool. (Aaltomaa et al, 2006, Brown and 
Gatter, 2002) 
 
Harper (Harper et al, 1992) reported that there was correlation with survival and grade 
but not stage while Cher (Cher et al, 1995) reported that Ki-67 index correlated with 
stage and grade of prostate cancer. Uzoaru (Uzoaru et al, 1998) commented that while 
Ki-67 provided prognostic information, and correlated inversely with survival, its value 




Ki-67 intensity and Ki-67 IPS were positively correlated with pre-operative serum PSA 
level as indicated by p values of 0.041 and 0.01 respectively (Table 8), indicating that 
overexpression of Ki-67 predicted higher pre-operative serum PSA levels which often is 
a sign of more aggressive prostate cancer. However, Ki-67 percentage was inversely 
correlated with pre-operative serum PSA level.  
 
There was positive correlation between p53 percentage and Ki-67 intensity. Direct 
correlation between p53 percentage and Ki-67 percentage, p53 IPS and Ki-67 IPS, p53 
IRS and Ki-67 IRS was shown in Table 8. This suggests that both p53 and Ki-67, when 
applied together, can provide additive prognostic information, as indicated by their 
statistically significant p values. 
 
4.7 Correlation of Androgen Receptor (AR) and p53, AR and Ki-67, p53 and Ki-67 
AR has been reported to be associated with markers of clinical aggressiveness, such as 
p53 and Ki-67 (Agoulnik et al, 2006, Li et al, 2004, Quinn et al, 2000). A trend was seen 
between AR percentage and p53 intensity, suggesting that higher percentage of AR 
immunostained was associated with more aggressive disease. 
 
Positive correlation of AR IPS and p53 IPS, AR IRS and p53 IRS also showed that 
increased AR stained was associated with worse prognosis. (Table 9)  
 
The positive correlation between p53 intensity and Ki-67 intensity also indicated 




4.8 Correlation of Neuroendocrine Markers with Clinicopathological Parameters 
Three neuroendocrine markers – CD56, chromogranin A (Chr A) and synaptophysin (Syn) 
have been studied to evaluate their roles in prostate cancer and there were no statistically 
significant findings. 
 
Helpap (Helpap and Köllerman, 1999) reported that prostate cells, which were stained 
positive for Chr A, represent post-mitotic cells. Vashchenko (Vashchenko and 
Abrahamsson, 2005) then went on to speculate that neuroendocrine cells might provide a 
link between neuroendocrine cell differentiation and tumorigenesis in prostate cancer.  
His group also suggested that the neuroendocrine peptides might activate proliferation of 
androgen-independent prostate cancer cells via transactivation of AR. However, 
Vashchenko was not able to explain the factors involved in the development of androgen 
independent neuroendocrine differentiation (NED) in prostate cancer (Vashchenko and 
Abrahamsson, 2005).  
 
Vashchenko (Vashchenko and Abrahamsson, 2005) reported that NED was more 
commonly found in prostatic carcinomas than cancers of the urogenital tract, especially 
since a relatively large population of neuroendocrine cells is found in the prostate. 
Vashchenko (Vashchenko and Abrahamsson, 2005)   also commented that NED is a 
common feature of prostatic carcinoma, regardless of the pathological stages. They found 
that neuroendocrine cells do not express AR. Positive correlation between NED and 
tumour grade, indicating poor prognosis, has been reported, but there are other groups 




(Vashchenko and Abrahamsson, 2005) attributed this conflicting finding to different 
patient cohorts studies, methodologies employed, amount of tissue sampled, and also 
variable distribution of neuroendocrine tumour cells. 
 
Abrahamsson (Abrahamsson, 1999) also reported similar findings as Vashchenko 
(Vashchenko and Abrahamsson, 2005). He mentioned that there were other groups who 
did not find correlation between the number of neuroendocrine cells and tumour stage, 
neuroendocrine differentiation and tumour grade. He also reported that one group 
demonstrated NED could enhance prediction of disease progression after radical 
prostatectomy; however, this was only confined to prostate cancer with Gleason score 5 
and 6.  
 
Like Vashchenko, Abrahamsson (Abrahamsson, 1999) found similar factors contributing 
to the conflicting findings. In addition, Abrahamsson also added that variation in 
interpretation, patient cohort, methodologies (such as type of samples assessed) have 
resulted in inconsistent interpretation. 
 
Abrahamsson (Abrahamsson, 1999) then reported that neuroendocrine cells have been 
shown to be in close proximity to proliferating cells, as demonstrated by Ki-67 
immunohistochemistry. He also suggested that NED could be one of the mechanisms 
involved in shift from androgen-dependent to androgen-independent prostate cancer 





This study did not find any statistically significant correlation between the 
neuroendocrine markers and the clinicopathological parameters studied. Only Gleason 
score and Syn expression showed a trend as indicated by a p value of 0.054, hence, 
suggesting that Syn expression was associated with increasing Gleason score. (Table 13) 
 
4.9 Correlation of Neuroendocrine Differentiation (NED) with Clinicopathological 
Parameters 
NED was defined by immunohistochemical expression of any one neuroendocrine 
differentiation biomarkers or a combination of two to three neuroendocrine differention 
biomarkers. Any unequivocal immunostaining observed was deemed positive expression. 
Immunohistochemical staining of sections for NED often involved a combination of two 
or NED markers.  
 
There were no statistically significant findings found between NED and various 
clinicopathological parameters. Although Jiborn et al (Jiborn et al, 1998) reported that 
there was significant correlation between NED and tumor grade,  Vashchenko 
(Vashchenko and Abrahamsson, 2005) also reported that there were other research 
groups, which did not find any statistically significant correlation between NED and 
tumor grade and prognosis. The conflicting observations could be due to selection of 
patient cohort, different methodologies employed, and even amount of tissues used for 
the evaluation studies (Aprikian et al, 1993, Bubendorf et al, 1996 Cohen et al, 1994, 




association between NED and any of clinicopathological parameters could not be 
established. 
 
Abrahamsson (Abrahamsson, 1999) and Vashchenko (Vashchenko and Abrahamsson, 
2005) reported that NED was found in almost all prostate adenocarcinomas – NED was 
found in 30-100% of the tumors. 51.0% of the cases studied were found to have NED as 
indicated by 51 cases which showed presence of NED with Gleason score of 7 or more  
in Table 14. 
 
4.10 Correlation of Neuroendocrine differentiation (NED) and AR, Ki-67 and p53 
Immunohistochemical Expression 
There was a good association between p53 and NED as indicated by a p value of 0.05. 
This concurred with the findings that prostate carcinomas found to have NED were often 
of poorer prognosis (Abrahamsson, 1999, Evans et al, 2006).  
 
Strong association between Ki-67 and NED was also found as indicated by a p value of 
0.003. This finding also concurred with those of Evan et al (Evan et al, 2006). 
 
It has been suggested that NED in prostate carcinoma was indeed associated with worse 
prognosis (Evans et al, 2006). These findings would aid in management of prostate cacer, 
especially in administering of androgen-deprivation therapy. Pathologists could perform 
immunohistochemical analysis by employing Ki-67, p53 and a couple of neuroendocrine 




benefit from androgen-deprivation therapy (ADT) or there is going to be a higher risk of 
biochemical recurrence. 
 
While the immunohistochemical expression would generate information for the clinicians 
to decide on the therapy to be administered, other established prognostic factors such as 
Gleason score, histological grade, extraprostatic extension and so forth, would have to be 
considered. This is especially important as there are currently no conclusive findings on 
employing NED as independent prognostic factor for prostate cancer. 
 
4.11 Conclusions
Gleason score, involvement of surgical margins, preoperative serum PSA level are 
currently prognostic markers used to assess disease progression and aggressiveness of 
prostate cancer after radical prostatectomy has been performed. However, as serum PSA 
screening level thresholds are affected by various factors such as age and weight, there is 
therefore a need to explore other biomarkers, which can aid in better prognostication and 
therefore, predict outcome of therapy. 
 
Molecular biomarkers have not been routinely applied to prostate cancer.  It is possible 
that applying these molecular biomarkers, be they existing or novel ones, could provide a 
better understanding of prostate cancer. Her-2/neu, AR, p53, Ki-67 and neuroendocrine 
markers – CD56, Chr A and Syn have been evaluated by immunohistochemistry to assess 




It is not conclusive to suggest that Her-2/neu is an ideal candidate as a prognostic marker, 
but there are reports in the literature suggesting that Her-2/neu is involved in prostate 
cancer development. The weakly positive to negative Her-2/neu immunostaining could 
be due to technical challenges related to the different archival age of tissues used in the 
study. 
 
AR findings have also been conflicting, but it is undeniable that AR played an important 
role in prostate cancer as demonstrated by us and other groups.  
 
Ki-67 and p53 have been shown to be associated with adverse prognosis as demonstrated 
by their positive correlations with high pre-operative serum PSA level (more than 4ng/ml) 
and Gleason score respectively. Ki-67 and p53 have also been shown to be directly 
correlated, hence, together with AR, can be used as potential adjunct to predict disease 
aggressiveness. 
 
There were no correlation found between the various clinicopathological parameters  and 
the neuroendocrine markers studied.  
 
Literature reports have suggested that neuroendocrine cells play a part in prostate cancer 
development, however, this study has not been able to demonstrate or suggest any 




Abrahamsson (Abrahamsson, 1999) suggested that many groups are reporting discrepant 
findings as a result of different patient cohorts being studied, applying different methods 
to study neuroendocrine differentiation in prostate cancer, variability in interpretation of 
observations, lack of standardization in scoring as well as the wide distribution of cells, 
which hinder proper sampling.  
 
4.12 Future Studies 
Mutation of p53 may not be properly assessed by immunohistochemistry alone – other 
techniques such as p53 gene sequencing may be needed to better define the type of p53 
mutations present, and hence determine its reliability as a prognostic marker in prostate 
cancer. 
 
There are still discrepancies whether AR overexpression can indicate disease 
aggressiveness. There are also suggestions that AR expression in specific cellular 
compartments may be relevant for further investigations. There may also be a need to 
specifically study the effects of AR localization in different prostate zones, as well as 
cellular compartments of the cytoplasm, nuclei, cytoplasmic membrane in relation to the 
clinicopathological parameters.  
 
Her-2/neu may be performed by in situ hybridization, so that this finding can be 
compared to that of Her-2/neu protein overexpression performed by 
immunohistochemistry. Her-2/neu is affected by fixation time, therefore, it is important 
Discussion 
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that the prostate gland is properly fixed for standardized durations prior to processing, as 
otherwise Her-2/neu immunostainng may yield unsatisfactory results. 
 
Neuroendocrine differentiation will also require more extensive study. Currently, there 
are not many published articles discussing neuroendocrine differentiation in prostate 
cancer. Neuroendocrine differentiation has been reported to have a role in prostate cancer, 
but this will require further investigations.  
 
Together with the proliferation marker Ki-67, AR and Her-2/neu, tumour suppressor p53 
and neuroendocrine markers, it is hoped that further evaluation can allow greater 
understanding of the biology of prostate cancer, and potentially integrate some of these 













Aaltomaa, S., Karja, V., Lippoen, P., Isotalo, T., Kankkunen, J-P., Talja, M., Mokka, 
R., Expression of Ki-67, Cyclin D1 and apotosis marker correlated with survival in 
prostate cancer patients treated by radical prostatectomy, Anticancer Research, 2006, 
26:4873-4878 
 
Abrahamsson, PA., Neuroendocrine differentiation in prostatic carcinoma, The 
Prostate, 1999, 39: 135-148 
 
Agoulnik, IU., Weigel, NL, Androgn receptor action in hormone-dependent and 
recurrent prostate cancer, Journal of Cellular Biochemistry, 2006, 99:362-372 
 
Alers, JC., Rochat, J., Krijtenburg, P-J., Hop, W.C.J., Kranse, R., Rosenberg, C., 
Tanke, Hans J., Schröder, Fritz H., van Dekkes, Herman., Identification of genetic 
markers for prostatic cancer progression, 2000, 80(6):931-942 
 
Aprikian, AG., Cordon-Carbo, C., Fair, WR., Reuter, VE., Characterization of 
neuroendocrine differentiation in human benign prostate and prostatic 
adenocarcinoma, Cancer, 1993, 71:3952-3965 
 
Bantis, A., Giannopoulos, A., Gonidi, M., Liossi,  A., Aggelonidou, E., Petrakakou, 
E., Athanassiades, P., Athanassiadou, P., Expression of p120, Ki-67 and pCNA as 
proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic 
value, Cytopathology, 2004, 15:25-31 
 
Bauman, DR., Steckelbroeck, S., Williams, MV., Deehl, DM., Penning, TM., 
Identification of the major oxidative 3α-hydroxysteroid dehydrogenase in human 
prostate that converts 5α-androstane-3α, 17β-diol to 5α-dihydrotestosterone: a 
potential therapeutic target for androgen-dependent disease, Molecular Endocrinology, 
2006, 20(2):444-458 
 
Battifora, H., The multitumour (sausage) tissue block: a novel method for 
immunohistochemical antibody testing, Laboratory Investigation, 1986, 55:244-248 
 
Berger, R., Lin, DL., Nieto, M., Sicinska, E., Garraway, LA., Adams, H., Signoretti, 
S., Hahm, WC., Loda, M., Androgen-dependent regulation of Her-2/neu in prostate 
cancer cells, Cancer Research, 2006; 66(11): 5723-5728 
 
Botchorishvili, G., Matikainen, MP., Lilja, H, Early prostate-specific antigen changes 
and the diagnosis and prognosis of prostate cancer, Current Opinion in Urology, 2009, 
19:221-226 
 
Boyle, P., Severi, G., Giles, GG., The epidemiology of prostate cancer, Urologic 
Clinics of North America, 2003, 209-217 
 
Brawley, O.W., Jani, A.B., Master, V., Prostate cancer and race, Current Problems in 






Brown, JC., Gatter, KC., Ki-67 protein: the immaculate deception, Histopathology, 
2002, 40:2-11 
 
Bubendorf, L., Sauter, G., Moch, H., Schmid, HP., Gasser, TC., Jordan, P., Ki 
labelling index: and independent predictor of progression on prostate cancer treated 
by radical prostatectomy, Journal of Pathology, 1996, 178:437-441 
 
Carle, J., Lloreta, J., Salido, M., Font, A., Suarez, Veronica B., Nogue, M., Domenech, 
M., Fabregat, X., Her-2/neu expression in prostate cancer : a dynamic process, 
Clinical Cancer Research, 2004, 10:4742-4745 
 
Carvalhal, GF., Daudi, SN., Kan, D., Mondo, D., Roehl, KA., Loeb, S., Catalona, WJ., 
Correlation between serum prostate-specific antigen and cancer volume in prostate 
glands of different sizes, Journal of Urology, 2010, 76(5):1072-1076 
 
Catalona, WJ., Loeb, S., Han, M., Viewpoint: expanding prostate cancer screening, 
Annals of Internal Medicine, 2006, 144(16):4414-43 
 
Chan, JM., Stampfer, MJ., Giovannucci, EL., What causes prostate cancer? A brief 
summary of the epidemiology, Seminars in Cancer Biology, 1998, 8:263-273 
 
Chejfec, G., Falkmer, S., Grimelius, L., Jacobson, B., Rodensjo, M., Wiedenmann, B., 
Franke, W.W., Lee, I., Gould, V.E., Synaptophysin: a new marker for pancreatic 
neuroendocrine tumours, The American Journal of Surgical Pathology, 1987, 11(4): 
241-247 
 
Cher, ML., Chew, K., Rosenau, W., Carroll, PR., Cellular proliferation in prostatic 
adenocarcinoma as assessed y bromodeoxyuridine updae and Ki-67 and PCNA 
expression, Prostate, 1995, 26:87-93 
 
Claudio, PP., Zamparelli, A., Garcia, FU., Claudio, L., Ammirati, G., Farina, A., 
Bovicelli, A., Russo, G., Giordano, GG., McGinnis, DE., Giordano, A., Cardi, G., 
Expression of cell-cycle-related proteins pRb21/p130, p107, p27kip1, p53, mdm-2, and 
Ki-67 (MIB-1) in prostatic gland adenocarcinoma, Clinicalcal Cancer Research, 2002, 
8:1808-1815 
 
Cohen, ML., Arber, DA., Coffield, S., Keegan, GT., McClintock, J., Speights, VO., 
Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to 
tumor progression, Cancer, 1994, 74:1899-1903 
 
Davies, P., Eaton, CL, Regulation of prostate growth, Journal of Endocrinology, 1991, 
131:5-17 
 
Dong, JT., Prevalent mutations in prostate cancer, Journal of Cellular Biochemistry, 
2006, 97: 433-447 
 
Drake, BF., Lathan, CS., Okechukwu, CA., Bennett, GG., Racial differences in 






Edwards, J., Traynor, P., Munro, AlF., Pirret, CF., Dunne, B., Bartlett, JMS, The role 
of HER 1 – HER 4 an EGRvIII in hormone-refractory prostate cancer, Clinical 
Cancer Research, 2006, 12(1): 123-130 
 
Epstein JI, Murphy WM, Disease of the Prostate Gland and Seminal Vesicles, 
William M Murphy, Urological Pathology, Second Edition, Philadelphia, W.B. 
Saunders Company, 1997, 149-150 
 
Epstein, JI, Allsbrook, WC., Mahul, BA., Lars, LE., ISUP Grading Committee, The 
2005 International Society of Urological Pathology consensus conference on Gleason 
grading of prostatic carcinoma, American Journal of Surgical Pathology, 2005, 29(9): 
1228-1242 
 
Erbersdobler, AFG., Schnöger, S., Gracefen, M., Hammer, P., Huland, H., Henke, 
RP., Tumour grade, proliferation,apotosis, microvessel density, p53, and bcl-2 in 
prostate cancers: differences beteen tumours located in the transition zone and in the 
peripheral zone, European Urology, 2002, 41:40-46 
 
Etzioni, RD., Ankerst, DP., Weiss, NS., Inoue, LYT., Thompson, IM., Is prostate-
specific antigen velocity useful in early detection of prostate cancer? A critical 
appraisal of the evidence, Journal of National Cancer Institute, 2007, 99:1510-1515 
 
Evans, A J., Humphrey, PA., Belani, JK, Theodorus H., Srigley, JR., Large cell 
neuroendocrine carcinoma of prostate – clinicopathologic summary of 7 cases of rare 
manifestation of advanced prostate cancer, American Journal of Surgical Pathology, 
2006, 30(6): 684-693 
 
Freeman, MR., HER 2/HER 3 heterodimers in prostate cancer: Whiter HER1/EGFR, 
Cancer Cell, 2004, 6:427-428 
 
Fradet, Y., Biomarkers in prostate cancer diagnosis and prognosis; beyond prostate-
specific antigen, Current Opinion in Urology, 2009, 19:243-46 
 
Gould, V.E., Lee, I., Wiedenman, B., Moll, R., Chejfec, G., Franke, W.W., 
Synaptophysin: A novel marker for neuron, certain neuroendocrine cells and their 
neoplasm, Human Pathology, 1986, 17(10): 979-983 
 
Guzzo, TJ., Vira, MA., Neway, W., Hwang, WT., Tomaszewski, KVA., Wein, AJ., 
Malkowicz, SB., Minimal tumor volume may provide additional prognostic 
information in good performance patients after radical prostatectomy, Journal of 
Urology, 2007, 69(6): 1147-1151 
 
Harper, ME., Goddard, L., Wilson, DW., Pathological and clinical associations of Ki-
67 defined growth fraction in human prostatic carcinoma, Prostate, 1992, 21:75-84 
 
Heidenberg, HB., Bauer, JJ., Mcleod, DG., Maul, JW., Srivastava, S., The role of p53 





Helpap, B., Köllerman, J., Undifferentiated carcinoma of the prostate with small cell 
features: immunohistochemical subtyping and reflections on histogenesis, Virchows 
Archives, 1999, 434:385-391 
 
Hoffman, RM., Viewpoint: limited prostate cancer screening, Annals of Internal 
Medicine, 2006, 144(16):438-440 
 
Jamali, M., Chetty, R., Predicting prognosis in gastroentero-pancreatic 
neuroendocrine tumours: an overview and the value of Ki-67 immunostaining, 
Endocrinology Pathology, 2008, 19:282-288 
 
Jensen, TA., Hammond, MEH., The tissue microarray-a technical guide for 
histologists, Journal of Histotechnology, 2001, 24:283-287 
 
Jensen, TA., Tissue microarray: advanced techniques, Journal of Histotechnology, 
2003, 26:101-104 
 
Jiborn, T., Bjartell, A., Abrahamsson, PA., Neuroendocrine differentiation in prostatic 
carcinoma during hormonal treatment, Urology, 1998, 51(4):585-589 
 
Jin, SK., p53 autophagy and tumour suppression, Autophagy, 2005, 1(3):171-173 
Jones, TD., Koch, MO., Lin, H., Liang, C., Visual estimation of tumour extent is not 
an independent predictor of prostate specific antigen recurrence, British Journal of 
Urology Internation, 2005, 96:1253-1257 
 
Kissane JM, Development and Structure of the Urogenital System, William M 
Murphy, Urological Pathology, Second Edition, Philadelphia, W.B. Saunders 
Company, 1997, 26-28 
 
Kolonel, LN., Fat, meat and prostate cancer, Epidemiology Reviews, 2001, 23:72-81 
 
Kominsky, S.L., Hobeika, A.C., Lake, F.A., Torres, B.A., Johnson, H.M., Down-
regulation of neu/HER-2 by interferon-γ in prostate cancer cells, Cancer Research, 
2000, 60: 3904-3908 
 
Konecki, DS., Benedum, U., Gerdes, HH., Huttnert, WB., The primary structure of 
human chromogranin A and pancreastatin, The Journal of Biological Chemistry, 1987, 
262(35):17026-17030 
 
Kononen J., Bubendorf, Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S., 
Torhorst, J., Minatsch, MJ., Sauter,G., Kallioiemi, OP., Tissue microarray for high-
throughput molecular profiling of tumour specimens, Nature Medicine, 1998, 
4(7):844-847 
 
Krupski, T., Petroni, GR., Frierson Jr, HF., Theodoresui, D., Microvessel density, p53, 
retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-
specific survival following radical prostatectomy for carcinoma of the prostate, 





Kuczyk, MA., Serth, J., Bokemeyer, C., Machtens, S., Minssan, A., Bathke, W., 
Hartmann, J., Jonas, U., The prognostic value of p53 for long term and recurrence free 
survival following radical prostatectomy, European Journal of Cancer, 1998, 
34(5):679-686 
 
Lanier, LL., Testi, R., Bindl, J., Phillips, JH., Identity of LLeu-19 (CD56) leukocyte 
differentiation antigen and neural cell adhesion molecule, Journal of Experimental 
Medcine, 1989, 169:2233-2238 
 
Lantuejoul, S., Laverriere, H., Strum, N., Moro, D., Frey, G., Brambilla, C., Brambilla, 
Elisabeth., NCAM(neural cell adhesion molecules) exoression in malignant 
mesotheliomas, Human Pathology, 2000, 31(4):415-421 
 
Lee, DK., Allareddy, Veerasuthpursh., O’Donnell, MA., Williams, RD., Konety, R., 
Does the interval between prostate biopsy and radical prostatectomy affect the 
immediate postoperative outcome?, British Journal of Urology International, 2006, 97: 
48-50 
 
Lee, HP., Ling, A., Chow, KY., Jin, A., Singapore Cancer Registry Interium report – 
trends in cancer incidence in Singapore 2002-2006, Singapore Cancer Registry, 2008 
 
Lee, WR, Giantonio, BJ., E-Hanks, G., Prostate cancer, Current Problems in Cancer, 
1994,18(6):295-357 
 
Lévesque, MH., El-Alfy, M., Cusan, L., Labrie, F., Androgen receptor as a potential 
sign of prostate cancer metastasis, The Prostate, 2009, 69 :1704-1711 
 
Li, R., Heydon, K., Hammond, M.E., Grignon, D.J., Roach III, M., Wolkov, H.B., 
Sandler, H.M., Shipley, W.U., Pollack, A., Ki-67 staining index predicts distant 
metastasis and survival in locally advanced prostate cancer treated with radiotherapy: 
an analysis of patients in radiation therapy oncology group protocol 86-10, Clinical 
Cancer Research, 2004, 10: 4118-4124 
 
Li, R., Wheeler, T., Dai, H., Frolov, A., Thompson, T., Ayala, G., High levels of 
androgen receptors is associated with aggressive clinicopathologic features and 
decreased biochemical recurrence-free survival in prostate cancer treated with radical 
prostatectomy, American Journal of Surgical Pathology, 2004, 28: 928-934 
 
Li, TH., Zhao, HJ., Yue, P., Beliakoff, J., Brooks, JD., Sun, Z., A promoting role of 
androgen receptor in androgen-sensitive and –insensitive prostate cancer cells, 
Nucleic Acids Research, 2007, 35(8):2767-76 
 
Liang, T., Liao, S., Inhibition of steroid 5α-reductase by specific aliphatic unsaturated 
fatty acids, Biochemistry Journal, 1992, 285:557-562 
 
Lichtenstein, P., Holm, NV., Verkasalo, PK, Iliadou, A., Kaprio, J., Koskenvuo, M., 
Pukkala, E., Skytthe, A., Hemminki, K., Environmental and heritable factors in the 
causation of cancer Analyses of cohorts of twins from Sweden, Denmark and Finland, 





Litvinov, AV., Griend, DJM., Lizamma, A., Dalrymple, S., Marzo, DAM., Drake, 
CG., Issacs, JT., Androgen receptor as a licensing factor for DNA replication in 
androgen-sensitive prostate cancer cells, PNAS, 2006, 103(41):15085-15090 
 
Lund Nielsen, TI., Johnsen, R., Vatten, LJ., Socioeconomic and lifestyle factors 
associated with the risk of prostate cancer, British Journal of Cancer, 2000, 82:1358-
1363 
 
Mellinhoff, IK., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J., Sawyers, CL., 
HER2/neu kinase-dependent modulation of androgen receptor function through 
effects on DNA binding and stability, Cancer Cell, 2004, 6:517-527 
 
Mohapatra, S., Chu, B., Zhao, X., Pledger, W.J., Accumulation of p53 and reductions 
in XIAP abundance promote the apoptosis of prostate cancer cells, Cancer Research, 
2005, 65(17):7717-7723 
 
Mori, R., Wang, Q., Quek, ML., Tarabolous, C., Cheung, E., Ye, W., Groshen, S., 
Hawes, D., Togo, S., Shimada, H., Daneberg, KD., Daneberg, PV., Pinski, JK., 
Prognostic value of the androgen receptor and its coactivators in patients with D1 
prostate cancer, Anticancer Research, 2008, 28:425-430 
 
Montironi, R., Uccheli, RM., Barbisan, F., Stramazzotti, D., Santinelli, A., Scarpelli, 
M., Beltran, AL., Her2 expression and gene amplification in pT2a Gleason score 6 
prostate cancer incidentally detected in cystoprostatectomies. Comparison with 
clinically detected androgen-dependent and androgen-independent cancer, Human 
Pathology, 2006, 37:1137-1144 
 
Moul, JW., Treatment of PSA only recurrence of prostate cancer after pior local 
therapy, Current Pharmaceutical Design, 2006, 12:785-798 
 
Nishio, Y., Yamada, Y., Kokubo, H., Nakamura, K., Aoki, S., Taki, T., Nobuaki, H., 
Nakagawa, A., Saga, S., Hara, K., Prognostic significance of Immunohistochemical 
expression of Her-2/neu oncoprotein in bone metastatic prostate cancer, Urology, 
2006, 68:110-115 
 
Noordzij, MA., van der Kwast, TH., Steenbrugge, GJ., Hop, WJC., Schroder, FH., 
The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-
term follow-up study with patients treated by radical prostatectomy, International 
Journal of Cancer, 1995, 62:252-258 
 
Obek, C., Lai, S., Civantos, F., Soloway, Mark., Age as a prognostic factor for disease 
rcurrence after radical prostatectomy, Urology, 1999, 54 :535-538 
 
Papadopoulos, I., Rudolph, P., Wirth, B., Weichert-Jacobsen, K., p53 expression, 
proliferation marker Ki-S5, DNA content and serum PSA: possible biopotential 
markers in human prostate cancer, Urology, 1996, 48:261-268 
 
Patel, AA., Chen, MH., Renshaw, AA., Amico, AVD., PSA failure following 
definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary 





Pelzer, AE., Tewari, A., Bektic, J., Berger, AP., Frauscher, F., Bartsch, Georg., 
Horninger, W., Detection rates and biologic significance of prostate cancer with PSA 
less than 4.0ng/ml:observation and clinical implications from Tyrol screening project, 
Urology, 2005, 66:1029-1033 
 
Penning, TM., Bauman, DR., Jin, Y., Rizner, TL., Identification of the molecular 
switch that regulates access of 5α-DHT to the androgen receptor, Molecular and 
Cellular Endocrinology, 2007, 265-266:77-82 
 
Penning, TM., Jin, Y., Rizner, TL., Bauman, DR., Pre-receptor regulation of the 
androgen receptor, Molecular Cellular Endocrinology, 2008, 281(1-2):1-8 
 
Petrescu, A., Marzan, L., Codreanu, O., Niculescu, L., Immunohistochemical 
detection of p53 protein as a prognostic indicator in prostate carcinoma, Romanian 
Journal of Morphology and Embryology, 2006, 47(2):143-146 
 
Pomerantz, MM., Freedman, ML., Kantoff, PW., Genetic determinants of prostate 
cancer risk, British Journal of Urology International, 2007, 100:241-248 
 
Quayle, SN., Mawji, NR., Wang, J., Sadar, MD., Androgen receptor decoy molecules 
block the growth of prostate cancer, PNAS, 2007, 104(4): 1331-1336 
 
Quinn, DI., Henshall, SH., Head, DaR., Golovsky, D., Wilson, JF., Brenner, PC., 
Turner, JJ., Delprado, W., Finlayson, RL., Prognostic significance of p53 nuclear 
accumulation in localized prostate cancer treated with radical prostatectomy, Cancer 
Research, 2000, 60:1585-1594 
 
Rangel, CS., The tissue microarray: helpful hints!, Journal of Histotechnology, 2002, 
25:93-96 
 
Ricciardelli, C., Jackson, MW., Choong, CS., Stahl, J., Marshall, VSR., Hosfall, DJ., 
Tilley, WD., Elevated levels of Her-2/neu and androgen receptor in clinically 
localized prostate cancer identifies metastatic potential, The Prostate, 2008, 830-838 
 
Richter, E., Srivastava, S., Dobi, A., Androgen receptor and prostate cancer, Prostate 
Cancer and Prostatic Disease, 2007, 1-5 
 
Rizner, TL., Lin, HK., Peehl, DM., Steckelbroeck, S., Bauman, DR., Penning, TM., 
Human type 3 3α-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and 
androgen metabolism in prostate cells, Endocrinology, 2003, 144(7):2922-2932 
 
Ross, JS., Sheenan, C., Hayner-Buchan, AM., Ambros, RA., Kallakuny, BVS., 
Kaufman, R., Fisher, HAG., Muraca, PJ., HER-2/neu gene amplification status in 
prostate cancer by fluorescence in situ hybridization, Human Pathology, 1997, 
28:827-833 
 
Ross, M.H., Pawlina, W., Histology a Text and Atlas with Correlated Cell and 





Ross, K.S., Guess, H.A., Carter. H.B., Estimation of treatment benefits when PSA 
screening for prostate cancer is discontinued at different ages. Urology, 2005, 
66:1038-1042 
 
Sant’agnese, PAD., Neuroendocrine cells of the prostate and neuroendocrine 
differentiation in prostatic carcinoma:review of morphologic aspects, Urology, 1998, 
51(Suppl 5A):121-124 
 
Schlaf, G., Salje, C., Poethke, R., Felgenhauer, K., Mader, M., A novel enzyme-
linked immunosorbent assay for determination of synaptophysin as compared with 
other quantification procedures, Journal of Neuroimmunology, 1996, 67:59-65 
 
Severson, RK., Grove, JS., Nomura, AMY., Stemmerman, GN., Body mass and 
prostate cancer: a prospective study, British Journal of Medicine, 1988, 297:713-715 
 
Shariat, S., Karam, J., Margulis, V., Karakiewicz, PI., New blood-based biomarkers 
for the diagnosis, staging and prognosis of prostate cancer, British Journal of Urology 
International, 2007, 1-9 
 
Shariat, SF., Bensalah, K., Karam, JA., Roehrborn, CG., Gallina, A., Lotan, Y., 
Slawin, Kevin M., Karakiewicz, Pierre I., Preoperative plasma HER2 and epidermal 
growth factor receptor for staging and prognostication in patients with clinically 
localized prostate cancer, Clinical Cancer Research, 2007, 13(18): 5377-5384 
 
Shi, Y., Brands, FH., Chatterjee, S., Feng, AC., Grosnen, S., Schewe, J., Liewkovsky, 
G., Cote, RJ., Her-2/neu expression in prostate cancer:high level of expression 
associated with exposure to hormone therapy and androgen independent disease, The 
Journal of Urology, 2001, 166:1514-1519 
 
Signoretti, S., Montironi, R., Manola, J., Altimari, A., Tam, C., Bubley, G., Balk, S., 
Thomas, G., Kaplan, I., Hlatky, L., Hahnfeldt, P., Kantoff, P., Loda, M., Her-2-neu 
expression and progression toward androgen independence in human prostate cancer, 
Journal of the National Cancer Institute, 2000, 92(23):1918-1925 
  
Singh, A., Jones, RF., Friedman, H., Hathir, S., Spps, Gyorgyike, ZA., Haass, GP., 
Expression of p53 and pRb in bladder and prostate cancers of patients having both 
cancers, Anticancer Research, 1999: 19:5415-5418 
 
Srigley, JR., Key issues in handling and reporting radical prostatectomy, Archives of 
Pathology Laboratory Medicine, 2006, 130:303-317 
 
Tan, Y., Hilmy, MH., Hung, H., Tan, PH., Initial experience with tissue microarray in 
a surgical pathology laboratory: technical considerations, The Journal of 
Histotechnology, 2004, 27: 113-117 
 
Uzoaru, I., Rubenstein, M., Mirochnik, Y., Slohodskoy, L., Shaw, M., Guinan, P., 
Evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer, 





Vaschenko, N., Abrahamsson, PA., Neuroendocrine differentiation in prostate cancer: 
implication for new treatment modalities, European Urology, 2005, 47:147-155 
 
Von Eschenbach A.C., Cancer of the prostate, Current Problems in Cancer, 1981, 
5(12): 3-54 
 
Walsh, P.C., Partin, A.W., Treatment of early stage prostate cancer: radical 
prostatectomy, Important Advances in Oncology. 1994, 211-223 
 
Wen, Y., Hu, MCT., Makino, K., Spohn, B., Bartholomeusz, G., Yan, DH., Hung, 
MC., HER-2/neu promotes androgen-independent survival and growth of prostate 
cancer cells through the Akt pathway, Cancer Research, 2000, 60:6841-6845 
 
Wolk, A., Diet, lifestyle and risk of prostate cancer, Acta Oncologica, 2005, 44:277-
281 
 
Young, B., Heath, SW., Male Reproductive System, Young B, Heath SW, Wheater’s 
Functional Histology – a text and colour atlas, Forth Edition, 2002, London, Churchill 
Livingsone, 337-339 
 
